Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study.
Standardized two-step testing of antibody activity in COVID-19 convalescent plasma.
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
Single-Cell Immunogenomic Approach Identified SARS-CoV-2 Protective Immune Signatures in Asymptomatic Direct Contacts of COVID-19 Cases.
Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2.
Epitope profiling using computational structural modelling demonstrated on coronavirus-binding antibodies.
Viral surface geometry shapes influenza and coronavirus spike evolution through antibody pressure.
Sequence analysis of the Emerging Sars-CoV-2 Variant Omicron in South Africa.
Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients.
An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 Neutralizing antibody levels in COVID-19 patients and vaccinees.
A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients.
Deep mutational scanning for therapeutic antibody engineering.
Llamanade: An open-source computational pipeline for robust nanobody humanization.
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status.
Host predictors of broadly cross-reactive antibodies against SARS-CoV-2 variants of concern differ between infection and vaccination.
Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.
A rapid real-time polymerase chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against SARS-CoV-2 in blood/serum.
Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine.
Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults.
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
A Multidimensional Cross-Sectional Analysis of Coronavirus Disease 2019 Seroprevalence Among a Police Officer Cohort: The PoliCOV-19 Study.
Application of SARS-CoV-2 Serology to Address Public Health Priorities.
Interpretations of SARS-CoV-2 IgM and IgG antibody titers in the seroepidemiological study of asymptomatic healthy volunteers.
From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine Against COVID-19, Day to Save the Life.
A novel multiplex electrochemiluminescent immunoassay for detection and quantification of anti-SARS-CoV-2 IgG and anti-seasonal endemic human coronavirus IgG.
Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens.
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies.
Analysis of B cell receptor repertoires reveals key signatures of systemic B cell response after SARS-CoV-2 infection.
Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire.
COVID-19 Antibody Detection and Assay Performance Using Red Cell Agglutination.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children.
SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients.
Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera.
A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
Expression of plasma IFN signaling-related miRNAs during acute SARS-CoV-2 infection and its association with RBD-IgG antibody response.
Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report.
Millisecond dynamic of SARS-CoV-2 spike and its interaction with ACE2 receptor and small extracellular vesicles.
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.
Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America.
A large-scale systematic survey of SARS-CoV-2 antibodies reveals recurring molecular features.
Secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon mRNA vaccination.
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance.
Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.
Precise location of two novel linear epitopes on the receptor-binding domain surface of MERS-CoV spike protein recognized by two different monoclonal antibodies.
Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity.
The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response.
Structure-Based Epitope Design: Toward a Greater Antibody-SARS-CoV-2 RBD Affinity.
Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years After Recovery From SARS.
Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report.
Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in 
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats.
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants.
Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization.
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.
Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Immunological and Preventive Effects of Hochuekkito and Kakkonto Against Coronavirus Disease in Healthcare Workers: A Retrospective Observational Study.
Extracellular Vimentin as a Target Against SARS-CoV-2 Host Cell Invasion.
Maternal-fetal immunologic response to SARS-CoV-2 infection in a symptomatic vulnerable population: A prospective cohort.
SARS-CoV-2 specific memory B-cells from individuals with diverse disease severities recognize SARS-CoV-2 variants of concern.
Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 na√Øve residents of nursing homes.
MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge.
Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution.
Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2.
Correlation of dried blood spots and plasma for quantification of Immunoglobulin (IgG) against Receptor binding domain and full length spike protein of SARS-CoV-2.
Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia.
Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine.
A Nucleocapsid-based Transcomplementation Cell Culture System of SARS-CoV-2 to Recapitulate the Complete Viral Life Cycle.
Production of Recombinant Replication-defective Lentiviruses Bearing the SARS-CoV or SARS-CoV-2 Attachment Spike Glycoprotein and Their Application in Receptor Tropism and Neutralisation Assays.
Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes.
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations.
Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview.
Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.
Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain.
Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape.
Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody.
Receptor-binding domain-based immunoassays for serosurveillance differentiate efficiently between SARS-CoV2-exposed and non-exposed farmed mink.
Postvaccination Multisystem Inflammatory Syndrome in Adult with No Evidence of Prior SARS-CoV-2 Infection.
Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval.
Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2.
Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring.
Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants.
Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma.
Evolution of the SARS-CoV-2 genome and emergence of variants of concern.
Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities.
Stabilization of the SARS-CoV-2 Receptor Binding Domain by Protein Core Redesign and Deep Mutational Scanning.
Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses.
Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.
Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials.
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2.
SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralising antibodies.
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies.
Humoral response to two doses of BNT162b2 vaccination in people with HIV.
Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucum√°n, Argentina.
Detection of SARS-CoV-2 spike protein binding to ACE2 in living cells by TR-FRET.
Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies.
Quantum dots assembly enhanced and dual-antigen sandwich structured lateral flow immunoassay of SARS-CoV-2 antibody with simultaneously high sensitivity and specificity.
Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro.
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2.
Dual electrochemical sensing of spiked virus and SARS-CoV-2 using natural bed-receptor (MV-gal1).
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity.
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses.
SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody.
Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine.
Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle.
CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology.
Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in 
Antibody Responses to SARS-CoV-2 Infection-Comparative Determination of Seroprevalence in Two High-Throughput Assays versus a Sensitive Spike Protein ELISA.
A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain.
Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects.
Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans.
Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight.
Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters.
Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study.
Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients.
Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2.
Monoclonal Human Antibodies That Recognise the Exposed N and C Terminal Regions of the Often-Overlooked SARS-CoV-2 ORF3a Transmembrane Protein.
High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2.
Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential.
Ultrasensitive Detection of COVID-19 Causative Virus (SARS-CoV-2) Spike Protein Using Laser Induced Graphene Field-Effect Transistor.
Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2.
IgG Study of Blood Sera of Patients with COVID-19.
SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study.
Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response.
Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
Myeloid dysregulation and therapeutic intervention in COVID-19.
Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19.
Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.
The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice.
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.
Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses.
Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination.
Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein.
Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
BSG/CD147 and ACE2 receptors facilitate SARS-CoV-2 infection of human iPS cell-derived kidney podocytes.
ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury.
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
Antibody cocktail effective against variants of SARS-CoV-2.
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity.
Detection of cross-reactive immunoglobulin A against the severe acute respiratory syndrome-coronavirus-2 spike 1 subunit in saliva.
12-month SARS-CoV-2 antibody persistency in a¬†Tyrolean COVID-19 cohort.
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination.
Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19.
Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2.
High-resolution epitope mapping and characterization of SARS-CoV-2 antibodies in large cohorts of subjects with COVID-19.
Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
Functional Antibodies Against SARS-CoV-2 Receptor Binding Domain Variants with Mutations N501Y or E484K in Human Milk from COVID-19-Vaccinated, -Recovered, and -Unvaccinated Women.
The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease.
N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study.
Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2.
Clinical Evaluation of Siemens SARS-CoV-2 Total Antibody assay and IgG assay using the Dimension EXL 200 in the Tokyo Metropolitan area.
Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients.
COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads.
Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.
SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2.
Introduction and rapid dissemination of SARS-CoV-2 Gamma Variant of Concern in Venezuela.
Design of a population-based longitudinal cohort study of SARS-CoV-2 incidence and prevalence among adults in the San Francisco Bay Area.
Contributions of single-particle cryoelectron microscopy toward fighting COVID-19.
Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases.
Affinity enhancement of CR3022 binding to RBD; 
Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4
Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design.
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.
Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs.
Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction.
Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii.
SARS-CoV-2 Antibody Response is Associated with Age in Convalescent Outpatients.
Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination.
SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike.
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19.
Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability.
Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection.
Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
Why are some coronavirus variants more infectious?
Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients.
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection.
Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2.
Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2.
Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.
Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.
Site-Specific and Stable Conjugation of the SARS-CoV-2 Receptor-Binding Domain to Liposomes in the Absence of Any Other Adjuvants Elicits Potent Neutralizing Antibodies in BALB/c Mice.
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice.
Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor.
SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains.
A Review of Human Coronaviruses' Receptors: The Host-Cell Targets for the Crown Bearing Viruses.
A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19.
A Collection of Designed Peptides to Target SARS-CoV-2 Spike RBD-ACE2 Interaction.
Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape.
Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
Interaction Analysis on the SARS-CoV-2 Spike Protein Receptor Binding Domain Using Visualization of the Interfacial Electrostatic Complementarity.
Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.
The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials.
Elucidating important structural features for the binding affinity of spike - SARS-CoV-2 neutralizing antibody complexes.
Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein.
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.
Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDS.
Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination.
SARS-CoV-2 infection despite high levels of vaccine-induced anti-Receptor-Binding-Domain antibodies: a study on 1110 health-care professionals from a northern Italian university hospital.
Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate.
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays.
Sustained Delivery of SARS-CoV-2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold.
Covid-19 vaccines and variants of concern: A review.
Mutation profile of SARS-CoV-2 spike protein and identification of potential multiple epitopes within spike protein for vaccine development against SARS-CoV-2.
Tear antibodies to SARS-CoV-2: implications for transmission.
Sandwich/competitive immuno-sensors on micro-interface for SARS-CoV-2 neutralizing antibodies.
"Polymutant" Spike Points Way Toward More Durable COVID-19 Vaccine.
SARS-CoV-2 infection induces cross-reactive autoantibodies against angiotensin II.
Camel nanobodies broadly neutralize SARS-CoV-2 variants.
mRNA Vaccines Induce Rapid Antibody Responses in Mice.
Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant.
Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins.
Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults.
ACE2‚Äâ:‚ÄâS1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics.
Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection.
Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern.
Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin.
Evaluation of a Novel Multiplex Platform for Simultaneous Detection of IgG Antibodies against the Four Main SARS-CoV-2 Antigens.
Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?
Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations.
Timing of SARS-CoV-2 vaccination during the third trimester of pregnancy and transplacental antibody transfer: a prospective cohort study.
Selective functional antibody transfer into the breastmilk after SARS-CoV-2 infection.
Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination.
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants.
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System.
A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence.
Immune Response of Neonates Born to Mothers Infected With SARS-CoV-2.
Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals.
Boosting of Cross-Reactive Antibodies to Endemic Coronaviruses by SARS-CoV-2 Infection but not Vaccination with Stabilized Spike.
The humanized nanobody RBD-1-2G tolerates the spike N501Y mutation to neutralize SARS-CoV-2.
Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran.
Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.
Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago.
Development of a recombinant vaccine containing a spike S1-Fc fusion protein induced protection against MERS-CoV in human DPP4 knockin transgenic mice.
Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters.
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models.
A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates.
Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera.
Polyclonal F(ab')
Elevated Humoral Immune Response to SARS-CoV-2 at High Altitudes Revealed by an Anti-RBD "
Quantitative Detection of Anti-SARS-CoV-2 Antibodies Using Indirect ELISA.
Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.
Casirivimab/Imdevimab: First Approval.
Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
The evaluation of novel oral vaccines based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta.
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel.
Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine.
Snake venom phospholipase A
Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021.
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
Presence of Antibodies to SARS-CoV-2 in Domestic Cats in Istanbul, Turkey, Before and After COVID-19 Pandemic.
The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19.
Unravelling the molecular interactions between the SARS-CoV-2 RBD spike protein and various specific monoclonal antibodies.
Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men.
Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain.
Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.
Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated healthcare workers.
Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV-2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle.
NMR-Based Analysis of Nanobodies to SARS-CoV-2 Nsp9 Reveals a Possible Antiviral Strategy Against COVID-19.
An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Evaluation of antibody response after COVID-19 vaccination of healthcare workers.
Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies.
Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals.
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study.
Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG.
Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child.
Longitudinal humoral antibody response to SARS-CoV-2 infection among healthcare workers in a New York City hospital.
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore.
Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines.
How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika.
Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43.
SARS-CoV-2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro.
Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.
Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.
An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants.
Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
Xeno-Nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.
Global Prevalence of Adaptive and Prolonged Infections' Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.
IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases.
Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2.
Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.
Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.
Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil.
Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.
Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks.
Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation.
Thymus Gland: A Double Edge Sword for Coronaviruses.
A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC.
Specific CD8
Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers.
Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2.
Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty
Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.
SARS-CoV-2-Specific Antibodies in Domestic Cats during First COVID-19 Wave, Europe.
Anti-SARS-CoV-2 hyperimmune globulin demonstrates potent neutralization and antibody-dependent cellular cytotoxicity and phagocytosis through N and S proteins.
Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment.
BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study.
Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants.
Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2.
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial.
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate.
Inborn errors of immunity: Recent progress.
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.
Single-dose replicating poxvirus vector-basedRBD vaccine drives robust humoral and T¬†cellimmune response against SARS-CoV-2 infection.
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers.
Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated Microthrombosis.
Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice.
BCEPS: A Web Server to Predict Linear B Cell Epitopes with Enhanced Immunogenicity and Cross-Reactivity.
Molecular Basis of a Dominant SARS-CoV-2 Spike-Derived Epitope Presented by HLA-A*02:01 Recognised by a Public TCR.
In Silico and In Vivo Evaluation of SARS-CoV-2 Predicted Epitopes-Based Candidate Vaccine.
Severity, Pathogenicity and Transmissibility of Delta and Lambda Variants of SARS-CoV-2, Toxicity of Spike Protein and Possibilities for Future Prevention of COVID-19.
Long Term Immune Response Produced by the SputnikV Vaccine.
Impact of Host Immune Status on Discordant Anti-SARS-CoV-2 Circulating B Cell Frequencies and Antibody Levels.
Receptor-Loaded Virion Endangers GPCR Signaling: Mechanistic Exploration of SARS-CoV-2 Infections and Pharmacological Implications.
The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose.
Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests-A Population-Based Evaluation.
Recombinant Protein Expression and Purification of N, S1, and RBD of SARS-CoV-2 from Mammalian Cells and Their Potential Applications.
Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples.
COVID-19 coagulopathies: Human blood proteins mimic SARS-CoV-2 virus, vaccine proteins and bacterial co-infections inducing autoimmunity: Combinations of bacteria and SARS-CoV-2 synergize to induce autoantibodies targeting cardiolipin, cardiolipin-binding proteins, platelet factor 4, prothrombin, and coagulation factors.
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.
Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2.
Single-cell profiling of proteins and chromatin accessibility using PHAGE-ATAC.
Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
Structure-guided antibody cocktail for prevention and treatment of COVID-19.
Immunogenicity and efficacy of ‚Ää‚Ää‚Ää‚Ää‚Ää‚Ää‚Ää‚Ää‚Ääheterologous ChAdOx1-BNT162b2 vaccination.
An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity.
Cowpea Mosaic Virus Nanoparticle Vaccine Candidates Displaying Peptide Epitopes Can Neutralize the Severe Acute Respiratory Syndrome Coronavirus.
DNA-Directed Patterning for Versatile Validation and Characterization of a Lipid-Based Nanoparticle Model of SARS-CoV-2.
Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody.
SARS-CoV-2 vaccine antibody response and breakthrough infection in dialysis.
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients.
SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy.
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses.
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy.
Quantum Optical Immunoassay: Upconversion Nanoparticle-based Neutralizing Assay for COVID-19.
Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening.
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants.
Immune characterization of a Colombian family cluster with SARS-CoV-2 infection.
SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects.
Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark.
SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma.
Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand.
Endothelial dysfunction and COVID-19 (Review).
Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern.
Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers.
Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies.
Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms.
Delta variant of COVID-19: A simple explanation.
BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents.
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: decline in antibodies 12 weeks after two doses.
SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study).
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD.
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks.
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine.
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41.
A poor and delayed anti-SARS-CoV2 IgG response is associated to severe COVID-19 in children.
In¬†vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential.
Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model.
Predicting Mutational Effects on Receptor Binding of the Spike Protein of SARS-CoV-2 Variants.
Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda.
The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines.
Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors.
Impact of Specific 
SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Na√Øve and Pre-Immune Humans.
Lessons in self-defence: inhibition of virus entry by intrinsic immunity.
A novel linear and broadly neutralizing peptide in the SARS-CoV-2 S2 protein for universal vaccine development.
No crossreactivity of anti-SARS-CoV-2 spike protein antibodies with Syncytin-1.
Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection.
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.
A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
ESC: a comprehensive resource for SARS-CoV-2 immune escape variants.
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial.
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein after infection and/or vaccination.
Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina.
The evolution of the mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America.

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies.
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
Optical Detection of SARS-CoV-2 Utilizing Antigen-Antibody Binding Interactions.
Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age.
SARS-CoV-2 Virus-Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response.
Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro.
Persistence of infectious SARS-CoV-2 particles for up to 37¬†days in patients with mild COVID-19.
Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance.
Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains.
Potential Utility of Radiopharmaceuticals in the Battle Against SARS-Cov-2 and COVID-19 Pandemic.
Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy.
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes.
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant.
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment.
Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination.
SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.
Glycan-Based Flow-Through Device for the Detection of SARS-COV-2.
Breastfeeding and the developmental origins of mucosal immunity: how human milk shapes the innate and adaptive mucosal immune systems.
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease.
SARS-CoV-2 Lambda (C.37): An emerging variant of concern?
PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2.
Prompt Reduction in CRP, IL-6, IFN-Œ≥, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19.
The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein.
N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains.
Œ±-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants.
Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.
A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
Identification of Unique Peptides for SARS-CoV-2 Diagnostics and Vaccine Development by an 
Peptides Derived From S and N Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Induce T Cell Responses: A Proof of Concept for T Cell Vaccines.
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients.
A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies.
Clinical and immunological characteristics in COVID-19 convalescent patients.
Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2.
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.
Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals.
Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2.
Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN¬Æ) and AZD1222 (COVISHIELD
Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins.
Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen.
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies).
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.
The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays.
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine.
SAS: A Platform of Spike Antigenicity for SARS-CoV-2.
Spread of Mink SARS-CoV-2 Variants in Humans: A Model of Sarbecovirus Interspecies Evolution.
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA.
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers.
Distant residues modulate conformational opening in SARS-CoV-2 spike protein.
mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants.
B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination.
virusMED: an atlas of hotspots of viral proteins.
Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection.
A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
SARS-CoV-2 seroassay performance and optimization in a population with high background reactivity in Mali.
A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice.
Molecular switches regulating the potency and immune evasiveness of SARS-CoV-2 spike protein.
SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19.
Mechanisms of SARS-CoV-2 entry into cells.
StatPearls
StatPearls
The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines.
Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times.
One-year sustained cellular and humoral immunities of COVID-19 convalescents.
An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models.
Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.
Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England.
SARS-CoV-2-Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals.
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H.
Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?
The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation.
Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies.
A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens.
Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model.
SARS-CoV-2 integral membrane proteins shape the serological responses of patients with COVID-19.
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge.
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals.
SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation.
Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers.
Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study.
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.
A highly potent antibody effective against SARS-CoV-2 variants of concern.
Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions.
Highly active engineered IgG3 antibodies against SARS-CoV-2.
Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection.
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Passive Immunity Should and Will Work for COVID-19 for Some Patients.
ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients.
Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.
SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells.
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant.
Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection.
SCIGA: Software for large-scale, single-cell immunoglobulin repertoire analysis.
Highly sensitive and ultra-rapid antigen-based detection of SARS-CoV-2 using nanomechanical sensor platform.
A Self-Biomineralized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice.
Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.
Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells.
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals.
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.
COVID-19 Repeated Convalescent Plasma Collection: Analysis of 149 Donations from 88 French Military Health Workers.
Viral S protein histochemistry reveals few potential SARS-CoV-2 entry sites in human ocular tissues.
Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants.
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.
Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression.
Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report.
Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque.
Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.
Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report.
A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine.
Multiepitope Proteins for the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD Regions of SARS-CoV-2.
Plant-Expressed Receptor Binding Domain of the SARS-CoV-2 Spike Protein Elicits Humoral Immunity in Mice.
COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity.
Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19.
Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q.
Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2.
Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2.
Development and Evaluation of Quantitative Immunoglobulin G Enzyme-Linked Immunosorbent Assay for the Diagnosis of Coronavirus Disease 2019 Using Truncated Recombinant Nucleocapsid Protein as Assay Antigen.
Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group.
Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency.
Aptamer-based electrochemical biosensor for rapid detection of SARS-CoV-2: Nanoscale electrode-aptamer-SARS-CoV-2 imaging by photo-induced force microscopy.
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination.
Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates.
Curious Binding Energy Increase between the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein and Angiotensin-Converting Enzyme 2 Adsorbed on a Silane Monolayer from Molecular Dynamics Simulations.
Antibody therapy for COVID-19.
Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians.
Identification of SARS-CoV-2¬†S RBD escape mutants using yeast screening and deep mutational scanning.
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm.
Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC).
Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma.
Virus structure and structure-based antivirals.
Dynamics of IgG-avidity and antibody levels after Covid-19.
Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273.
E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients.
Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses.
Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma.
Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy.
Synthetic SARS-CoV-2 Spike-Based DNA Vaccine Elicits Robust and Long-Lasting Th1 Humoral and Cellular Immunity in Mice.
SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms.
Seroprevalence of antibodies against severe acute respiratory coronavirus 2 (SARS-CoV-2) in household dogs in Japan.
Sero-prevalence of anti-SARS-CoV-2 antibodies among healthcare workers: A multicenter study from Egypt.
Development of a novel label-free all-fiber optofluidic biosensor based on Fresnel reflection and its applications.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard.
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.
An ultrapotent pan-Œ≤-coronavirus lineage B (Œ≤-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope.
Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of SARS-CoV-2 Infection in Adult Syrian Hamsters.
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations.
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.
Differentiation of immortalized human multi-lineage progenitor to alveolar type 2-like cells: angiotensin-converting enzyme 2 expression and binding of severe acute respiratory syndrome coronavirus 2 spike and spike 1 proteins.
Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial.
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.
SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings.
Roles of Two Major Domains of the Porcine Deltacoronavirus S1 Subunit in Receptor Binding and Neutralization.
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Impact of rituximab on COVID-19 outcomes.
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.
A surrogate cell-based SARS-CoV-2 spike blocking assay.
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.
The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display.
Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants.
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs.
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2.
Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants.
Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination.
Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant.
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial.
Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential.
Molecular Level Dissection of Critical Spike Mutations in SARS-CoV-2 Variants of Concern (VOCs): A Simplified Review.
Takotsubo syndrome after receiving the COVID-19 vaccine.
The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
The First Chemically-Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped 
Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile.
Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction.
Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection.
Low Environmental Temperature Exacerbates Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters.
SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
The biological and clinical significance of emerging SARS-CoV-2 variants.
A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies.
Intrauterine immunizations trigger antigen-specific mucosal and systemic immunity in pigs and passive protection in suckling piglets.
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
The role of Bruton's tyrosine kinase in the immune system and disease.
Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients.
The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein.
A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels.
S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis.
Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19.
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies.
Design and development of plastic antibodies against SARS-CoV-2 RBD based on molecularly imprinted polymers that inhibit 
Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease.
Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study.
Genetic drift in the genome of SARS COV-2 and its global health concern.
Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
Saliva SARS-CoV-2 Antibody Prevalence in Children.
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky.
Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.
Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection.
N-Terminal Modification of Gly-His-Tagged Proteins with Azidogluconolactone.
Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama.
Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.
Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection.
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.
Rapid Detection of SARS-CoV-2 Antigens and Antibodies Using OFET Biosensors Based on a Soft and Stretchable Semiconducting Polymer.
Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs.
Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity.
MALDI-ToF protein profiling as a potential rapid diagnostic platform for COVID-19.
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
Fiber-optic label-free biosensor for SARS-CoV-2 spike protein detection using biofunctionalized long-period fiber grating.
Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study.
Acute exercise increases immune responses to SARS CoV-2 in a previously infected man.
A novel IgM intranasal intervention against SARS-CoV-2.
Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients.
Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2 Variants.
Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian Variant) From Predicted Spike Protein Structure.
SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic.
Recombinant 
Efficacy and safety of BNT162b2 vaccination in¬†patients with solid cancer receiving anticancer therapy - a single centre prospective study.
Decline of antibody titres 3¬†months after two doses of BNT162b2 in non-immunocompromised adults.
Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines.
A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site.
SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients.
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.
The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice.
Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity.
Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2.
Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif.
Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.
Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines.
One-Step, Wash-free, Nanoparticle Clustering-Based Magnetic Particle Spectroscopy Bioassay Method for Detection of SARS-CoV-2 Spike and Nucleocapsid Proteins in the Liquid Phase.
Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.
A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma.
Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report.
Neutralizing antibodies for the prevention and treatment of COVID-19.
A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2.
Vaccines efficacy to SARS-CoV-2 variants require holistic knowledge of viral immunology and protein biochemistry.
Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation.
A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern 
The Importance of Glycosylation in COVID-19 Infection.
Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals.
Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles.
Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape.
RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates.
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice.
Toxicity and Local Tolerance of COVID- 
Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine.
Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.
Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants.
Trivalent Subunit Vaccine Candidates for COVID-19 and Their Delivery Devices.
SARS-CoV-2 Antibody Response to the BNT162b2 mRNA Vaccine in Persons with Past Natural Infection.
Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients.
Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity.
Impact of the Delta variant on vaccine efficacy and response strategies.
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection.
Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.
Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2.
Pathogenic Mechanisms of Vaccine-Induced Immune Thrombotic Thrombocytopenia in People Receiving Anti-COVID-19 Adenoviral-Based Vaccines: A Proposal.
Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies.
SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.
Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants.
Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein.
Seroprevalence of SARS-CoV-2 among high-risk healthcare workers in a MERS-CoV endemic area.
Development of ACE2 autoantibodies after SARS-CoV-2 infection.
Current status of therapeutic monoclonal antibodies against SARS-CoV-2.
Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.
Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Similar antibody responses against SARS-CoV-2 in HIV uninfected and infected individuals on antiretroviral therapy during the first South African infection wave.
Immunogenicity of engineered Lactobacillus plantarum expressing porcine epidemic diarrhea virus S1 gene.
Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection.
A virus-free cellular model recapitulates several features of severe COVID-19.
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.
Surface Engineering of Graphene through Heterobifunctional Supramolecular-Covalent Scaffolds for Rapid COVID-19 Biomarker Detection.
The 27th Annual Prostate Cancer Foundation Scientific Retreat Report.
A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels.
Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern.
Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity.
Phylogenicity of B.1.1.7 surface glycoprotein, novel distance function and first report of V90T missense mutation in SARS-CoV-2 surface glycoprotein.
Isolation of Antibodies Against the Spike Protein of SARS-CoV from Pig Serum for Competitive Immunoassay.
Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses.
Mechanical activation of spike fosters SARS-CoV-2 viral infection.
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies.
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants.
Illuminating the Fc dependence of SARS-CoV-2 neutralization.
Comparison of Anti-SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine.
Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer.
mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern.
Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines.
Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity.
Multiple Roles of SARS-CoV-2 N Protein Facilitated by Proteoform-Specific Interactions with RNA, Host Proteins, and Convalescent Antibodies.
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2.
Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima - Peru.
Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history.
Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor.
Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership.
SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity.
Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel.
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter.
Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test.
A vaccine based on the receptor-binding domain of the spike protein expressed in glycoengineered 
A decoy strategy to activate the immune system.
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.
Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies.
Rapid induction of antigen-specific CD4
In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.
Peptide Platform as a Powerful Tool in the Fight against COVID-19.
Serological Detection of SARS-CoV-2 Antibodies in Naturally-Infected Mink and Other Experimentally-Infected Animals.
Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates.
Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses.
Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy.
Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population.
Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
SARS-CoV-2 Infection in Dogs and Cats from Southern Germany and Northern Italy during the First Wave of the COVID-19 Pandemic.
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19.
Virus-Induced CD8
Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains.
Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines.
The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review.
Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge.
DNA Vaccine Administered by Cationic Lipoplexes or by In Vivo Electroporation Induces Comparable Antibody Responses against SARS-CoV-2 in Mice.
Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1.
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines.
Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein.
Recombinant SARS-CoV-2 Nucleocapsid Protein: Expression, Purification, and Its Biochemical Characterization and Utility in Serological Assay Development to Assess Immunological Responses to SARS-CoV-2 Infection.
Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection.
An Autochthonous Outbreak of the SARS-CoV-2 P.1 Variant of Concern in Southern Italy, April 2021.
The rapid adaptation of SARS-CoV-2-rise of the variants: transmission and resistance.
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.
Small Structural Proteins E and M Render the SARS-CoV-2 Pseudovirus More Infectious and Reveal the Phenotype of Natural Viral Variants.
Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis.
SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes.
Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers.
Development and Evaluation of a Set of Spike and Receptor Binding Domain-Based Enzyme-Linked Immunosorbent Assays for SARS-CoV-2 Serological Testing.
Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test.
Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-Œ≥ ELISpot.
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers.
Affinity Tag Coating Enables Reliable Detection of Antigen-Specific B Cells in Immunospot Assays.
Molecular Dynamics Simulation Study of the Interaction between Human Angiotensin Converting Enzyme 2 and Spike Protein Receptor Binding Domain of the SARS-CoV-2 B.1.617 Variant.
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.
Optimization and application of silver staining of non-glycosylated and glycosylated proteins and nucleic acids for agarose native gel electrophoresis.
An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility.
Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants.
ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker.
Update: Drug treatment options for coronavirus disease 2019 (COVID-19).
Investigation of Interaction between the Spike Protein of SARS-CoV-2 and ACE2-Expressing Cells Using an In Vitro Cell Capturing System.
Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses.
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern.
Intranasal vaccination.
Neutralization of MERS coronavirus through a scalable nanoparticle vaccine.
Systematic Review on Treatment Trials of Tocilizumab- A Repurposing Drug Against COVID-19.
Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York.
The impact of spike mutated variants of SARS-CoV2 Alpha, Beta, Gamma, Delta, and Lambda on the efficacy of subunit recombinant vaccines.
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates.
SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment.
Serological survey of SARS-CoV-2 incidence conducted at a rural West Virginia hospital.
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant.
Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab.
Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus.
Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination.
Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity.
SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.
Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion.
Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects.
SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector function.
Analysis of the avian coronavirus spike protein reveals heterogeneity in the glycans present.
Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2.
Sequential Profiling of Anti-SARS CoV-2 IgG Antibody in Post COVID-19 Patients.
Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection.
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and na√Øve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
Anti-SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report.
Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein.
Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
SARS-CoV-2 RNA and antibody detection in breast milk from a prospective multicentre study in Spain.
Evaluation of a Visually-Read Rapid Antigen Test Kit (SGA V-Chek) for Detection of SARS-CoV-2 Virus.
Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
One-shot identification of SARS-CoV-2¬†S RBD escape mutants using yeast screening.
Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity.
EDTA-Induced Pseudothrombocytopenia Up to 9 Months After Initial COVID-19 Infection Associated with Persistent Anti-SARS-CoV-2 IgM/IgG Seropositivity.
Poliovirus Vaccination Induces a Humoral Immune Response That Cross Reacts With SARS-CoV-2.
N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation.
Rarely Recognized Antibody Diversification in Covid-19 Evolution to Counteract Advanced SARS-CoV-2 Evasion Strategies, and Implications for Prophylactic Treatment.
Activation or exhaustion of CD8
Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results.
Evolving threat.
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.
Association Between S100b Levels and COVID-19 Pneumonia: A Case Control Study.
COVID-19: the CaMKII-like system of S protein drives membrane fusion and induces syncytial multinucleated giant cells.
The Emergence and Spread of Novel SARS-CoV-2 Variants.
Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection.
SARS-CoV-2 Antibodies in Breast Milk After Vaccination.
Establishment of Full-Length cDNA Clones and an Efficient Oral Infection Model for Feline Coronavirus in Cats.
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants.
Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery.
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients.
Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2.
Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry.
Generation and Characterization of a Nanobody Against SARS-CoV.
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.
Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants.
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action.
Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy.
Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1
Controversy surrounding the Sputnik V vaccine.
Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2.
Sensitive Immunodetection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern 501Y.V2 and 501Y.V1.
Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers.
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review.
Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein.
Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers.
Massive surge of mRNA expression of clonal B-cell receptor in patients with COVID-19.
Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease.
SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development.
Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and Œ±OX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
Age, obesity and hyperglycaemia: Activation of innate immunity initiates a series of molecular interactions involving anionic surfaces leading to COVID-19 morbidity and mortality.
Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients.
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
CRISPR-based peptide library display and programmable microarray self-assembly for rapid quantitative protein binding assays.
Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response.
GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
Vaccination versus infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity maturation.
Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort.
SARS-CoV-2 receptor-binding mutations and antibody contact sites.
HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine.
Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function.
Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo.
Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?
Repertoire of Rearranged Immunoglobulin Heavy Chain Genes in Russian Patients With B-Cell Lymphoproliferative Diseases.
CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID-19: A potential link to molecular pathophysiology?
Humoral and Cell-Mediated Immune Response in Colostrum from Women Diagnosed Positive for SARS-CoV-2.
The rapid diagnosis and effective inhibition of coronavirus using spike antibody attached gold nanoparticles.
Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.
Structural Basis for SARS-CoV-2 Nucleocapsid Protein Recognition by Single-Domain Antibodies.
An electrochemical immunosensor using SARS-CoV-2 spike protein-nickel hydroxide nanoparticles bio-conjugate modified SPCE for ultrasensitive detection of SARS-CoV-2 antibodies.
Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies.
TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A¬†phase¬†1 randomized clinical trial.
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients.
Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand.
The use of pseudotyped coronaviruses for the screening of entry inhibitors: Green tea extract inhibits the entry of SARS-CoV-1, MERS-CoV, and SARS-CoV-2 by blocking receptor-spike interaction.
Fusion Peptide of SARS-CoV-2 Spike Rearranges into a Wedge Inserted in Bilayered Micelles.
Antibodies to SARS-CoV-2 in dogs and cats, USA.
COVID-19 mRNA Vaccination in Lactation: Assessment of adverse effects and transfer of anti-SARS-CoV2 antibodies from mother to child.
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern.
Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity.
Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.
Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization.
SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.
Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity.
Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.
Construction of Fluorescent Immunosensor Quenchbody to Detect His-Tagged Recombinant Proteins Produced in Bioprocess.
Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives.
Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine.
Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.
Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2.
Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms.
The Characteristics of Spike Glycoprotein Gene of Swine Acute Diarrhea Syndrome Coronavirus Strain CH/FJWT/2018 Isolated in China.
CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines 
Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management.
Stability of SARS-CoV-2 IgG in multiple laboratory conditions and blood sample types.
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses.
A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants.
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.
The Effects of AŒ≤
SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling.
Absence of SARS-CoV-2 Antibodies in Natural Environment Exposure in Sheep in Close Contact with Humans.
Diffuse C4d staining of peritubular capillaries in renal allograft following bamlanivimab therapy.
Single-reaction multi-antigen serological test for comprehensive evaluation of SARS-CoV-2 patients by flow cytometry.
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants.
Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2.
Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks.
Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses.
The Potential Role of an Aberrant Mucosal Immune Response to SARS-CoV-2 in the Pathogenesis of IgA Nephropathy.
Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants.
COVID-19 Biomarkers and Advanced Sensing Technologies for Point-of-Care (POC) Diagnosis.
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model.
Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study.
Inhibition of elastase enhances the adjuvanticity of alum and promotes anti-SARS-CoV-2 systemic and mucosal immunity.
An in-depth in silico and immunoinformatics approach for designing a potential multi-epitope construct for the effective development of vaccine to combat against SARS-CoV-2 encompassing variants of concern and interest.
SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein.
Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies.
Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination.
Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients.
Deep geometric representations for modeling effects of mutations on protein-protein binding affinity.
Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.
Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy.
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes.
Broad betacoronavirus neutralization by a stem helix-specific human antibody.
Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.
Longitudinal observation of antibody responses for 14¬†months after SARS-CoV-2 infection.
Immunoglobulin G antibody response¬†to the Sputnik V vaccine:¬†previous SARS-CoV-2 seropositive individuals may need just one vaccine dose.
Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view.
Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction.
Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines.
An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory.
Janus Emulsion Biosensors for Anti-SARS-CoV-2 Spike Antibody.
Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.
Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection.
Origin, phylogeny, variability and epitope conservation of SARS-CoV-2 worldwide.
SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies.
The development of 
Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection.
Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7¬†months post-infection.
Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies.
Boron doped diamond thin films for the electrochemical detection of SARS-CoV-2 S1 protein.
Cerebrospinal fluid cytokine, chemokine, and SARS-CoV-2 antibody profiles in children with neuropsychiatric symptoms associated with COVID-19.
SARS-CoV-2 in Transit: Characterization of SARS-CoV-2 Genomes From Venezuelan Migrants in Colombia.
Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike.
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice.
A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.
Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.
SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects.
The role of antibody-based troponin detection in cardiovascular disease: A critical assessment.
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.
Neutralizing antibody responses against SARS-CoV-2 spike receptor-binding domain 13 months after the recovery from the disease.
COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers.
Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy.
A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding.
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers.
SARS-CoV-2 pseudovirus infectivity and expression of viral entry-related factors ACE2, TMPRSS2, Kim-1, and NRP-1 in human cells from the respiratory, urinary, digestive, reproductive, and immune systems.
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.
A functional assay for serum detection of antibodies against SARS-CoV-2 nucleoprotein.
The prevalence of SARS-CoV-2 antibodies in triage-negative patients and staff of a fertility setting from lockdown release throughout 2020.
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.
A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples.
A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays.
IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro.
Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization.
Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia.
Rapid and stable mobilization of CD8
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
√úberantibodies From Recovered COVID-19 Patients Could Spur New Therapeutics and Vaccines.
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
Cohabitation With a Known Coronavirus Disease 2019 Case Is Associated With Greater Antibody Concentration and Symptom Severity in a Community-Based Sample of Seropositive Adults.
Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries.
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets.
Dynamics of breast milk antibody titer in the six months following SARS-CoV-2 infection.
The dynamics of quantitative SARS-CoV-2 antispike IgG response to BNT162b2 vaccination.
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike.
A Rapid and Affordable Point-of-care Test for Detection of SARS-Cov-2-Specific Antibodies Based on Hemagglutination and Artificial Intelligence-Based Image Interpretation.
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.
B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect 
Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay.
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies.
Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination.
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India.
Insights into the virologic and immunologic features of SARS-COV-2.
SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study.
Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient.
An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System.
Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.
Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study.
Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics.
Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors.
Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo.
Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion.
Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2.
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.
Ongoing global and regional adaptive evolution of SARS-CoV-2.
New Impedimetric Sandwich Immunosensor for Ultrasensitive and Highly Specific Detection of Spike Receptor Binding Domain Protein of SARS-CoV-2.
Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination.
Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants.
Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.
Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice.
Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19.
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice.
Seroprevalence of SARS-CoV-2 antibodies among rural healthcare workers.
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays.
Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization.
Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks.
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants.
Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants.
A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters.
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis.
SARS-CoV-2 Receptor Binding Domain as a Stable-Potential Target for SARS-CoV-2 Detection by Surface-Enhanced Raman Spectroscopy.
Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection.
Vaccine serologic responses among transplant patients associate with COVID-19 infection and T peripheral helper cells.
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates.
Xeno-nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.
Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles.
SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'.
The role of micronutrient and immunomodulation effect in the vaccine era of COVID-19.
Broad sarbecovirus neutralization by a human monoclonal antibody.
Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.
Early antibody responses associated with survival in COVID19 patients.
Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist.
Lentil lectin derived from 
Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
IgA Nephropathy After SARS-CoV-2 Vaccination.
Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.
A theoretical strategy for acceleration of human immune response against SARS-CoV-2: a fusion protein harboring virus-binding and pre-exposed antigen domains.
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
SARS-CoV-2 variants, a still unfinished story.
Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19.
Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies.
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
B cell receptor (BCR) guided mechanotransduction: Critical hypothesis to instruct SARS-CoV-2 specific B cells to trigger proximal signalling and antibody reshaping.
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.
SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence.
Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies.
Free Energy Landscapes from SARS-CoV-2 Spike Glycoprotein Simulations Suggest that RBD Opening Can Be Modulated via Interactions in an Allosteric Pocket.
Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity.
Next-generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire.
Receptor-binding domain recombinant protein RBD219-N1C1 on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates.
Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review.
Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.
Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2.
AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for Enhanced Detection of SARS-CoV-2 Specific Nucleocapsid and Receptor Binding Domain IgG.
Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
Intranasal gene therapy to prevent infection by SARS-CoV-2 variants.
Amplification-Free SARS-CoV-2 Detection Using Nanoyeast-scFv and Ultrasensitive Plasmonic Nanobox-Integrated Nanomixing Microassay.
Pulling-Force Spinning Top for Serum Separation Combined with Paper-Based Microfluidic Devices in COVID-19 ELISA Diagnosis.
Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV.
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods.
Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative.
Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.
The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting.
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma.
Interaction of serum proteins with SARS-CoV-2 RBD.
One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.
Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model.
Systems vaccinology of the BNT162b2 mRNA vaccine in humans.
Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.
Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T¬†cells.
A Peptide Vaccine Candidate Tailored to Individuals' Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects.
Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.

Antibodies against Receptor Binding Domain of SARS-CoV-2 spike protein induced by BNT162b2 vaccine: results from a pragmatic, real-life study.
A novel combined vaccine against classical swine fever and porcine epidemic diarrhea viruses elicits a significant Th2-favored humoral response in mice.
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.
Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2.
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
In¬†vitro and in¬†vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19.
Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.
Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses.
Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil.
Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
Severe Clinical Worsening in COVID-19 and Potential Mechanisms of Immune-Enhanced Disease.
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2.
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
A facile chemoenzymatic synthesis of SARS-CoV-2 glycopeptides for probing glycosylation functions.
Rapid and accurate agglutination-based testing for SARS-CoV-2 antibodies.
Predicted structural mimicry of spike receptor-binding motifs from highly pathogenic human coronaviruses.
Detection and Neutralization of SARS-CoV-2 Using Non-conventional Variable Lymphocyte Receptor Antibodies of the Evolutionarily Distant Sea Lamprey.
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.
Stable trimer formation of spike protein from porcine epidemic diarrhea virus improves the efficiency of secretory production in silkworms and induces neutralizing antibodies in mice.
Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia.
Seropositive Reaction Rates of 9 B-Cell Epitopes of the SARS-CoV-2 Spike Protein and the Relationship between the Epitopes and Neutralizing Antibody.
The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience.
N-terminal domain of SARS CoV-2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals.
Antibody titres decline 3-month post-vaccination with BNT162b2.
One-year persistence of neutralizing anti-SARS-CoV-2 antibodies in dialysis patients recovered from COVID-19.
Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers.
Dimeric IgA is a specific biomarker of recent SARS-CoV-2 infection.
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain.
All-Atom Simulations and Free-Energy Calculations of Antibodies Bound to the Spike Protein of SARS-CoV-2: The Binding Strength and Multivalent Hydrogen-Bond Interactions.
Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing.
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.
Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants.
Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody.
Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients.
Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients.
A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus.
Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding.
Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial.
Sex-based clinical and immunological differences in COVID-19.
Serological response to a single dose of a SARS-CoV-2 mRNA vaccine.
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants.
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study.
Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological study.
SARS-CoV-2: Origin, Evolution, and Targeting Inhibition.
High throughput surface plasmon resonance imaging method for clinical detection of presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.
Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.
A photo-electrochemical aptasensor for the determination of severe acute respiratory syndrome coronavirus 2 receptor-binding domain by using graphitic carbon nitride-cadmium sulfide quantum dots nanocomposite.
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.
Tracking the pipeline: immunoinformatics and the COVID-19 vaccine design.
Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2.
Assessment of serological assays for identifying high titer convalescent plasma.
Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19.
Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell.
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.
Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern.
COVID-19: individual and herd immunity.
IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection.
Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation.
N-Glycosylation of the SARS-CoV-2 Receptor Binding Domain Is Important for Functional Expression in Plants.
Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses.
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.
Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs.
More Is Always Better Than One: The N-Terminal Domain of the Spike Protein as Another Emerging Target for Hampering the SARS-CoV-2 Attachment to Host Cells.
Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine.
Full-Length Computational Model of the SARS-CoV-2 Spike Protein and Its Implications for a Viral Membrane Fusion Mechanism.
Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants.
BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers.
Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine.
Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?
SARS-Cov-2 Natural Infection in a Symptomatic Cat: Diagnostic, Clinical and Medical Management in a One Health Vision.
Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2.
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals.
Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera.
A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA.
Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart.
A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects.
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination.
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.
SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2.
Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.
A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro.
Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination.
Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?
Epitope-Specific Response of Human Milk Immunoglobulins in COVID-19 Recovered Women.
Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.
Protein Engineering in the Design of Protein-Protein Interactions: SARS-CoV-2 Inhibitors as a Test Case.
V483A: an emerging mutation hotspot of SARS-CoV-2.
Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
sMAdCAM: IL-6 Ratio Influences Disease Progression and Anti-Viral Responses in SARS-CoV-2 Infection.
Engineered single-domain antibodies tackle COVID variants.
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.
Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity.
Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.
A 3.4-√Ö cryo-electron microscopy structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles.
Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity.
Conventional and Nanotechnology-Based Sensing Methods for SARS Coronavirus (2019-nCoV).
CyDisCo production of functional recombinant SARS-CoV-2 spike receptor binding domain.
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays.
Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies.
Highly selective and sensitive sandwich immunosensor platform modified with MUA-capped GNPs for detection of spike Receptor Binding Domain protein: A precious marker of COVID 19 infection.
Targeting neuropilins as a viable SARS-CoV-2 treatment.
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
IgA potentiates NETosis in response to viral infection.
A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs.
Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19.
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
Replication and vaccine protection of multiple infectious bronchitis virus strains in pheasants (Phasianus colchicus).
An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research.
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.
Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates.
Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story.
Impact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein.
Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease.
Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection.
How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility.
Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients.
Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections.
Effect of Methylene Blue Pathogen Inactivation on the Integrity of Immunoglobulin M and G.
Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2.
Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative.
A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients.
Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
Dynamics of Antibodies to Various Antigens of the SARS-CoV-2 Coronavirus in Patients with Confirmed COVID-19 Infection.
Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test.
Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis.
SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses.
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
Rapid generation of potent antibodies by autonomous hypermutation in yeast.
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity.
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.
TRP channels in COVID-19 disease: Potential targets for prevention and treatment.
Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species.
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.
SARS-CoV-2 Serologic Assays Dependent on Dual-Antigen Binding Demonstrate Diverging Kinetics Relative to Other Antibody Detection Methods.
Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity.
A longitudinal follow-up of COVID-19 patients in the convalescent phase showed recovery in radiological results, the dynamics of lymphocytes, and a decrease in the level of IgG antibody: a single-centre, observational study.
Longitudinal Antibody Dynamics Against Structural Proteins of SARS-CoV-2 in Three COVID-19 Patients Shows Concurrent Development of IgA, IgM, and IgG.
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.
Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARS‚ÄëCoV‚Äë2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients.
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa.
Allosteric Cross-Talk among Spike's Receptor-Binding Domain Mutations of the SARS-CoV-2 South African Variant Triggers an Effective Hijacking of Human Cell Receptor.
Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses.
Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease.
Structures of synthetic nanobody-SARS-CoV-2-RBD complexes reveal distinct sites of interaction and recognition of variants.
Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States.
Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers.
In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients.
Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain.
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.
Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity.
Production of the Receptor-binding Domain of the Viral Spike Proteins from 2003 and 2019 SARS CoVs and the Four Common Human Coronaviruses for Serologic Assays and Inhibitor Screening.
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Innentitelbild: Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies (Angew. Chem. 23/2021).
Development of an indirect ELISA for detecting swine acute diarrhoea syndrome coronavirus IgG antibodies based on a recombinant spike protein.
Rational optimization of a human neutralizing antibody of SARS-CoV-2.
Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4
Chimeric Virus-like Particles of Universal Antigen Epitopes of Coronavirus and Phage QŒ≤ Coat Protein Trigger the Production of Neutralizing Antibodies.
COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
Large-Scale Identification of T-Cell Epitopes Derived From Severe Acute Respiratory Syndrome Coronavirus 2 for the Development of Peptide Vaccines Against Coronavirus Disease 2019.
The landscape of antibody binding in SARS-CoV-2 infection.
Inclusion of cGAMP within virus-like particle vaccines enhances their immunogenicity.
Purification and characterization of the receptor-binding domain of SARS-CoV-2 spike protein from 
Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species.
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots.
In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients.
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva.
Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.
Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers.
Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19.
Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination.
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T¬†cell responses.
Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
Human IgG and IgA responses to COVID-19 mRNA vaccines.
Epitope-Functionalized Gold Nanoparticles for Rapid and Selective Detection of SARS-CoV-2 IgG Antibodies.
Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results.
Attractive and repulsive residue fragments at the interface of SARS-CoV-2 and hACE2.
SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques.
Facile and rapid detection of SARS-CoV-2 antibody based on a noncompetitive fluorescence polarization immunoassay in human serum samples.
COVID-19 Spike Protein Induced Phononic Modification in Antibody-Coupled Graphene for Viral Detection Application.
Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
Mapping Potential Antigenic Drift Sites (PADS) on SARS-CoV-2 Spike in Continuous Epitope-Paratope Space.
Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: preventing COVID-19 and treating tumor progression.
Evidence for Deleterious Antigenic Imprinting in SARS-CoV-2 Immune Response.
Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity.
Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry.
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
AI-guided discovery of the invariant host response to viral pandemics.
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
Rapidly emerging SARS-CoV-2 B.1.1.7 sub-lineage in the United States of America with spike protein D178H and membrane protein V70L mutations.
Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA.
Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies.
A serological aptamer-assisted proximity ligation assay for COVID-19 diagnosis and seeking neutralizing aptamers.
Prospects of Neutralizing Nanobodies Against SARS-CoV-2.
Potent and Persistent Antibody Response in COVID-19 Recovered Patients.
COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; revisiting the Western New York approach as the pandemic evolves.
SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance.
Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models.
Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination.
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant.
COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men.
SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy.
SARS-CoV-2 in pregnancy and possible transfer of immunity: assessment of peripartal maternal and neonatal antibody levels and a longitudinal follow-up.
Analysis of the molecular mechanism of SARS-CoV-2 antibodies.
Can We AlphaFold Our Way Out of the Next Pandemic?
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model.
Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays.
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry.
Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.
FnCas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2 variants on a paper strip.
Identification of Novel T-Cell Epitopes on Infectious Bronchitis Virus N Protein and Development of a Multi-epitope Vaccine.
Anaphylaxis is a rare reaction in COVID-19 vaccination.
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection.
Senolytics reduce coronavirus-related mortality in old mice.
A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine.
Human Type II Taste Cells Express Angiotensin-Converting Enzyme 2 and Are Infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Efficient Identification of High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Plasma Samples by Pooling Method.
Be aware of SARS-CoV-2 spike protein: There is more than meets the eye.
Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.
Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies.
Functional characterization of SARS-CoV-2 vaccine elicited antibodies in immunologically na√Øve and pre-immune humans.
Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year.
SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care.
Identification of COVID-19 B-cell epitopes with phage-displayed peptide library.
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity.
Comparative immunogenicity analysis of intradermal versus intramuscular administration of SARS-CoV-2 RBD epitope peptide-based immunogen In¬†vivo.
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.
How we secured a COVID-19 convalescent plasma procurement scheme in Japan.
Protocol for constructing large size human antibody heavy chain variable domain (V
Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain.
Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay.
Highly efficient CD4+ T¬†cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs.
Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus.
Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice.
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.
Synthetic proteins for COVID-19 diagnostics.
Tackling COVID-19 with neutralizing monoclonal antibodies.
Expression of the SARS-CoV-2 Receptor ACE2 in Human Retina and Diabetes-Implications for Retinopathy.
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain.
A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform.
Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern.
IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.
Affordable oral health care: dental biofilm disruption using chloroplast made enzymes with chewing gum delivery.
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.
Combination of a Sindbis-SARS-CoV-2 spike vaccine and Œ±OX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima - Peru.
Divergent early antibody responses define COVID-19 disease trajectories.
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab 
Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays.
Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection.
Diagnostic Potential of a Luminex-Based Coronavirus Disease 2019 Suspension Immunoassay (COVID-19 SIA) for the Detection of Antibodies against SARS-CoV-2.
Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections.
The Spike of Concern-The Novel Variants of SARS-CoV-2.
Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay.
A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques.
Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro.
Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants.
Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.
Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice.
Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies.
Virological Correlates of IgM-IgG Patterns of Response to SARS-CoV-2 Infection According to Targeted Antigens.
Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity.
Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America.
Design and Numerical Analysis of a Graphene-Coated SPR Biosensor for Rapid Detection of the Novel Coronavirus.
Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein.
Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease.
Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2.
Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
Mutation in a SARS-CoV-2 Haplotype from Sub-Antarctic Chile Reveals New Insights into the Spike's Dynamics.
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.
Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms.
A Reliable Indirect ELISA Protocol for Detection of Human Antibodies Directed to SARS-CoV-2 NP Protein.
Human CD4
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination.
A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity.
The first Chinese national standards for SARS-CoV-2 neutralizing antibody.
Detection of antibodies against SARS-CoV-2 both in plasma pools for fractionation and in commercial intravenous immunoglobulins produced from plasma collected in Italy during the pandemic.
Rapid detection of SARS-CoV-2 using a radiolabeled antibody.
Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine.
Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.
Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike.
Current Strategies of Antiviral Drug Discovery for COVID-19.
Fast SARS-CoV-2 virus detection using disposable cartridge strips and a semiconductor-based biosensor platform.
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors.
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.
Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study.
Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates.
Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?
SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2.
Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots.
Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2¬†(SARS-CoV-2) inhibit receptor binding and viral replication.
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
Are the new SARS-CoV-2 variants resistant against the vaccine?
Facile Determination of COVID-19 Seroconversion via Nonradiative Energy Transfer.
Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2.
Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center.
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil.
Severe acute respiratory syndrome coronavirus 2 as a potential cause of type 1 diabetes facilitated by spike protein receptor binding domain attachment to human islet cells: An illustrative case study and experimental data.
Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors.
DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss.
Unknown/enigmatic functions of extracellular ASC.
Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma.
Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides.
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.
Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants' spike protein-an in silico analysis.
Immune evasion of SARS-CoV-2 variants of concern is driven by low affinity to neutralizing antibodies.
Effective high-throughput isolation of fully human antibodies targeting infectious pathogens.
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals.
SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.
Antibodies: what makes us stronger.
Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection.
Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity.
Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2.
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans.
The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2.
Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept.
SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T¬†cell recognition.
Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests.
Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors.
Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors.
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies.
SARS-CoV-2 variants: A double-edged sword?
Glycosylation is a key in SARS-CoV-2 infection.
SARS-CoV-2 nanobodies 2.0.
Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets.
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.
Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets.
NMR Based SARS-CoV-2 Antibody Screening.
Humoral Immune Response of SARS-CoV-2-Infected Patients with Cancer: Influencing Factors and Mechanisms.
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
Development of a Unique Rapid Test to Detect Anti-bodies Directed Against an Extended RBD of SARS-CoV-2 Spike Protein.
Novel SARS-CoV-2 variants: the pandemics within the pandemic.
B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.
Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020

multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection.
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy.
Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy.
Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis.
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response.
Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies.
Energy Landscape of the SARS-CoV-2 Reveals Extensive Conformational Heterogeneity.
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
SARS-CoV-2 receptor binding domain-specific antibodies activate platelets with features resembling the pathogenic antibodies in heparin-induced thrombocytopenia.
A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.
Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization.
Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.
High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.
Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden.
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
SARS-CoV-2 vaccines: anamnestic response in previously infected recipients.
Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins.
Cross-Neutralizing CRF01_AE-Infected Plasma from Malaysia Targets CD4-Binding Site of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein.
Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study.
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.
Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq.
One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses.
SARS-Cov-2 spike protein fragment 674-685 protects mitochondria from releasing cytochrome c in response to apoptogenic influence.
Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis.
Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study.
A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2‚ÄâS-protein and human ACE2 interaction.
A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.
A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.
Inhibition of SARS-CoV-2 reproduction using Boswellia carterii: A theoretical study.
Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.
Susceptibility of animal species to experimental SARS-CoV-2 (
Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Naive Nursing Home Residents.
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.
Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility.
Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs.
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression.
Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies.
Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation.
Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein.
Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans.
An NTD supersite of attack.
Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-April 5, 2021.
Automated, flow-based chemiluminescence microarray immunoassay for the rapid multiplex detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (CoVRapid CL-MIA).
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor.
Structural basis for broad coronavirus neutralization.
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.
A Combined Molecular Docking and Density Functional Theory Nuclear Magnetic Resonance Study of Trans-Dehydrocrotonin Interacting with COVID-19 Main Protease and Severe Acute Respiratory Syndrome Coronavirus 2 3C-Like Protease.
Vaccination strategy and anti - SARS-CoV-2‚ÄâS titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19.
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor.
Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2.
Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations.
SARS-CoV-2 in patients with cancer: possible role of mimicry of human molecules by viral proteins and the resulting anti-cancer immunity.
Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design.
A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation.
A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.
Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center.
Mice with induced pulmonary morbidities display severe lung inflammation and mortality following exposure to SARS-CoV-2.
ACE2-based decoy receptors for SARS coronavirus 2.
A hemagglutination-based, semi-quantitative test for point-of-care determination of SARS-CoV-2 antibody levels.
LY-CoV1404 potently neutralizes SARS-CoV-2 variants.
SARS -CoV-2 T-cell immunity to variants of concern following vaccination.
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.
Impaired T-cell and antibody immunity after COVID-19 infection in chronically immunosuppressed transplant recipients.
Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.
Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein.
Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.
Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8¬†months post-symptom onset.
Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients.
Antibodies and Vaccines Target RBD of SARS-CoV-2.
Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design.

The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC
Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2.
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.
Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease.
Glucose-regulated protein (GRP78) is an important cell surface receptor for viral invasion, cancers, and neurological disorders.
Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1.
Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.
Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11.
The Contribution of Biophysics and Structural Biology to Current Advances in COVID-19.
Single-Domain Antibodies for the Detection of SARS-CoV-2 Nucleocapsid Protein.
Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment.
Delayed production of neutralizing antibodies correlates with fatal COVID-19.
Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells.
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity.
A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice.
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.
The non-specific antiviral activity of polysulfates to fight SARS-CoV-2, its mutants and viruses with cationic spikes.
Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
Determinants of IgG antibodies kinetics after severe and critical COVID-19.
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria.
Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients.
Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes in COVID-19 Patients.
First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.
Receptor-binding Domain Severe Acute Respiratory Syndrome Coronavirus 2-specific Antibodies in Human Milk From Mothers With Coronavirus Disease 2019 Polymerase Chain Reaction or With Symptoms Suggestive of Coronavirus Disease 2019.
Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein.
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.
Extensive genetic diversity with novel mutations in spike glycoprotein of severe acute respiratory syndrome coronavirus 2, Bangladesh in late 2020.
Corrigendum: Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective.
Single-Cell RNA Sequencing Analysis of the Immunometabolic Rewiring and Immunopathogenesis of Coronavirus Disease 2019.
Antibody Responses in COVID-19: A Review.
Seroprevalence of SARS-CoV-2 antibodies in university students: Cross-sectional study, December 2020, England.
Evaluation of SARS-CoV-2 total antibody detection via a lateral flow nanoparticle fluorescence immunoassay.
Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection.
Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2.
Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva.
Expression of SARS coronavirus 1 spike protein from a herpesviral vector induces innate immune signaling and neutralizing antibody responses.
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in¬†vitro.
A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter.
Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies.
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.
Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production.
A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response.
Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort.
Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies.
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles.
From Multiplex Serology to Serolomics-A Novel Approach to the Antibody Response against the SARS-CoV-2 Proteome.
AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate.
Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19.
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Neutralizing Antibody Therapeutics for COVID-19.
A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model.
Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies.
Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective.
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic.
Innate immune-mediated antiviral response to SARS-CoV-2 and convalescent sera a potential prophylactic and therapeutic agent to tackle COVID-19.
Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails.
Human neutralizing antibodies to SARS-CoV-2: views and perspectives from Professor Linqi Zhang at Tsinghua University.
Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.
Reactivity of human antisera to codon optimized SARS-CoV2 viral proteins expressed in 
Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score.
Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes.
Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein.
Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening".
Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques.
Insertions in SARS-CoV-2 genome caused by template switch and duplications give rise to new variants of potential concern.
A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope.
Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates.
Human Taste Cells Express ACE2: a Portal for SARS-CoV-2 Infection.
Nanotraps for the containment and clearance of SARS-CoV-2.
Construction and applications of SARS-CoV-2 pseudoviruses: a mini review.
The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination.
Production in Escherichia coli of recombinant COVID-19 spike protein fragments fused to CRM197.
A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests.
A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
Monoclonal antibody therapy in COVID-19.
NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies.
Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.
Experimental Identification of Immuno- dominant B-cell Epitopes from SARS-CoV-2.
Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations.
TRIM21 inhibits porcine epidemic diarrhea virus proliferation by proteasomal degradation of the nucleocapsid protein.
A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System.
Serologic Screening of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Cats and Dogs during First Coronavirus Disease Wave, the Netherlands.
Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection.
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors.
Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 
Current state of diagnostic, screening and surveillance testing methods for COVID-19 from an analytical chemistry point of view.
Antibodies for COVID-19 - which, when and how long?
Proteome-wide epitope mapping identifies a resource of antibodies for SARS-CoV-2 detection and neutralization.
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.
Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
The basis of a more contagious 501Y.V1 variant of SARS-CoV-2.
Structure and function analysis of a potent human neutralizing antibody CA521
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera.
Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.
A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters.
Microchip-based structure determination of low-molecular weight proteins using cryo-electron microscopy.
StatPearls
StatPearls
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity.
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.
Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus.
Binding of the SARS-CoV-2 Spike Protein to the Asialoglycoprotein Receptor on Human Primary Hepatocytes and Immortalized Hepatocyte-Like Cells by Confocal Analysis.
Antibody-Dependent Enhancement and the Critical Pattern of COVID-19: Possibilities and Considerations.
Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization.
Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation.
Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells.
Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.
The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD.
An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory.
Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies.
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
Development of in-house ELISAs for the detection of anti-SARS‚ÄëCoV‚Äë2 RBD and N IgG and IgM antibodies in biological samples.
Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals.
COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.
Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!
Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum.
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models.
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
First case of postmortem study in a patient vaccinated against SARS-CoV-2.
Structural and Functional Characterization of SARS-CoV-2 RBD Domains Produced in Mammalian Cells.
SARS-CoV-2 spike therapeutic antibodies in the age of variants.
SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.
RBD-specific polyclonal F(ab¬¥)
Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation.
SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients.
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.
Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay.
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.
The SARS-CoV-2 Spike variant D614G favors an open conformational state.
Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic.
SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen.
The dream vaccine.
Distinct antibody and memory B cell responses in SARS-CoV-2 na√Øve and recovered individuals following mRNA vaccination.
Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination.
Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers.
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.
Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers.
Integrin Activation Enables Sensitive Detection of Functional CD4
Progress in research on the S protein as the target of COVID-19 vaccines.
Antibody evasion by the P.1 strain of SARS-CoV-2.
Efficient Human Cell Coexpression System and Its Application to the Production of Multiple Coronavirus Antigens.
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors.
Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019.
Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum.
mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition.
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody.
Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity.
Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2.
Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality.
SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques.
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.
Early T¬†cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset.
SARS‚ÄëCoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice.
Rigid monoclonal antibodies improve detection of SARS-CoV-2 nucleocapsid protein.
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19.
SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses.
Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data.
Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2.
COVID-19 and HIV-Associated Immune Reconstitution Inflammatory Syndrome: Emergence of Pathogen-Specific Immune Responses Adding Fuel to the Fire.
Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies.
Structure-based Design of a Specific, Homogeneous Luminescence Enzyme Reporter Assay for SARS-CoV-2.
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany.
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.
Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.
Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.
Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates.
COVID-19 serology in nephrology healthcare workers.
Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival.
Latest Russian vaccine comes with a big dose of mystery.
SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.
High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19.
A human coronavirus evolves antigenically to escape antibody immunity.
Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.
Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors.
Immunoinformatic approach to design a multiepitope vaccine targeting non-mutational hotspot regions of structural and non-structural proteins of the SARS CoV2.
A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.
Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate.
A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients.
IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays.
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
Preparing for the Future - Nanobodies for Covid-19?
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray.
A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling.
Vertical Flow Cellulose-Based Assays for SARS-CoV-2 Antibody Detection in Human Serum.
Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
Serology Testing Demonstrates That Antibodies to SARS-CoV-2 S1-RBD Correlate with Neutralization of Virus Infection of Vero E6 Cells.
Efficient Maternofetal Transplacental Transfer of Anti- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Antibodies After Antenatal SARS-CoV-2 BNT162b2 Messenger RNA Vaccination.
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429.
Analysis of glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein.
Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2.
A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes.
Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model.
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants.
A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential.
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.
Immunotherapy in psoriasis.
Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape.
Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19.
Immunity to SARS-CoV-2: Lessons Learned.
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex¬†vivo ELISpot assay.
Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.
Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19.
Expression and Purification of a PEDV-Neutralizing Antibody and Its Functional Verification.
Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG.
SARS-CoV-2 Infection and Antibody Response in a Symptomatic Cat from Italy with Intestinal B-Cell Lymphoma.
Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test.
Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice.
Diagnostic Value of IgM and IgG Detection in COVID-19 Diagnosis by the Mobile Laboratory B-LiFE: A Massive Testing Strategy in the Piedmont Region.
SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations.
Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.
Detection and Genome Sequencing of SARS-CoV-2 in a Domestic Cat with Respiratory Signs in Switzerland.
In Translation: FcRn across the Therapeutic Spectrum.
Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2.
SARS-CoV-2 Seroprevalence in Household Domestic Ferrets (
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response.
Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19.
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.
Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.
Pregnancy alters interleukin-1 beta expression and antiviral antibody responses during severe acute respiratory syndrome coronavirus 2 infection.
Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
Systems serology detects functionally distinct coronavirus antibody features in children and elderly.
Designed proteins assemble antibodies into modular nanocages.
Development and Validation of a Multiplex Microsphere Immunoassay Using Dried Blood Spots for SARS-CoV-2 Seroprevalence: Application in First Responders in Colorado, USA.
Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class.
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
Computational epitope map of SARS-CoV-2 spike protein.
Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period.
Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine.
Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents.
T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity.
Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.
B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies.
A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants.
Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.
Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects.
Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.
A comparative review of immunoassays for COVID-19 detection.
Detection and Profiling of Human Coronavirus Immunoglobulins in Critically Ill Coronavirus Disease 2019 Patients.
Role of Tissue Factor in the Pathogenesis of COVID-19 and the Possible Ways to Inhibit It.
Upregulation of CCR4 in activated CD8
Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms.
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.
Development and validation of indirect ELISA for antibody detection against different protein antigens of porcine epidemic diarrhea virus in the colostrum and milk of sows.
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
B Cell Response to Vaccination.
Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design.
Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.
Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.
Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.
Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study.
Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients.
Engineered Ultra-High Affinity Synthetic Antibodies for SARS-CoV-2 Neutralization and Detection.
The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.
Molecular characterization of interactions between the D614G variant of SARS-CoV-2¬†S-protein and neutralizing antibodies: A computational approach.
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection.
A rapid, point-of-care red blood cell agglutination assay detecting antibodies against SARS-CoV-2.
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.
Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population.
IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity.
The evolutionary dynamics of endemic human coronaviruses.
The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
The emerging plasticity of SARS-CoV-2.
Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers.
Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients.
Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19.
Correlation of Automated Chemiluminescent Method with Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titers in Convalescent COVID-19 Plasma Samples: Development of Rapid, Cost-Effective Semi-Quantitative Diagnostic Methods.
COVID-19 Pandemic: Review of Contemporary and Forthcoming Detection Tools.
A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients.
Monoclonal antibodies capable of binding SARS-CoV-2 spike protein receptor-binding motif specifically prevent GM-CSF induction.
SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses.
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study.
Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation.
Anti-SARS-CoV-2 Serology persistence over time in COVID-19 Convalescent Plasma Donors.
SARS-CoV-2 seroassay optimization and performance in a population with high background reactivity in Mali.
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD.
Predicting the Efficacy of COVID-19 Convalescent Plasma Donor Units with the Lumit Dx anti-Receptor Binding Domain Assay.
A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies.
Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike.
Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants.
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses.
Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies.
Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motif.
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes.
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening.
Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva.
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity.
Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein.
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays.
The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2.
Interferon system deficiencies exacerbating severe pandemic virus infections.
The antigenic anatomy of SARS-CoV-2 receptor binding domain.
Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses.
Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure.
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.
A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.
A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies.
Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.
Prevalence of SARS-CoV-2 Specific Antibodies in Asymptomatic Hemodialysis Patients.
A Dual Target-Directed Single Domain-Based Fusion Protein Against Interleukin-6 Receptor Decelerate Experimental Arthritis Progression Via Modulating JNK Expression.
DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice.
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
COVID-19 - BLOOD GROUPS, ANTIBODIES AND CONVALESCENT PLASMA.
Long-term persistence of RBD
MXene-Graphene Field-Effect Transistor Sensing of Influenza Virus and SARS-CoV-2.
Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand.
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
Back to normal; serological testing for COVID-19 diagnosis unveils missed infections.
SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.
Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence.
Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.
A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies.
Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies.
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein.
SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19.
MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19.
SARS-CoV-2 antibody seroprevalence after the first wave among workers at a community healthcare system in the Greater Boston area.
Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations.
Structural impact on SARS-CoV-2 spike protein by D614G substitution.
Development of multi-epitope peptide-based vaccines against SARS-CoV-2.
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
Establishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low-Incidence Settings.
SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals.
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.
Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days.
The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization.
Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.
The conundrum of current anti-SARS-CoV-2 vaccines.
The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2.
The effect of spike mutations on SARS-CoV-2 neutralization.
Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain.
Evaluation of the automated LIAISON
Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies.
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.
Why blood group A individuals are at risk whereas blood group O individuals are protected from SARS-CoV-2 (COVID-19) infection: A hypothesis regarding how the virus invades the human body via ABO(H) blood group-determining carbohydrates.
Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2.
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Virus vaccines: proteins prefer prolines.
The great escape? SARS-CoV-2 variants evading neutralizing responses.
Audio Interview: The Implications of Changes in the Structural Biology of SARS-CoV-2.
Immunoinformatic analysis of structural and epitope variations in the spike and Orf8 proteins of SARS-CoV-2/B.1.1.7.
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
Shedding of Culturable Virus, Seroconversion, and 6-Month Follow-up Antibody Responses in the First 14 Confirmed Cases of Coronavirus Disease 2019 in the United States.
Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2.
Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.
Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma.
SARS-CoV-2 rapidly adapts in aged BALB/c mice and induces typical pneumonia.
Susceptibility of white-tailed deer (
Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection.
Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2.
Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane.
Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Na√Øve and Recovered Individuals Following mRNA Vaccination.
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.
Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma Units.
Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants.
Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization.
Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates.
Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters.
Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.
One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.
A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.
Phage Display Technique as a Tool for Diagnosis and Antibody Selection for Coronaviruses.
Serological evidence of SARS-CoV-2 and co-infections in stray cats in Spain.
Lost in deletion: The enigmatic ORF8 protein of SARS-CoV-2.
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Neutralizing Activity of BNT162b2-Elicited Serum.
Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies.
Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features.
Severe COVID-19 Pneumonia is Associated with Increased Plasma Immunoglobulin G Agonist Autoantibodies Targeting the 5-Hydroxytryptamine 2A Receptor.
The Potential of Developing Pan-Coronaviral Antibodies to Spike Peptides in Convalescent COVID-19 Patients.
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution.
The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19.
Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.
On the Prevalence and Potential Functionality of an Intrinsic Disorder in the MERS-CoV Proteome.
Single-Molecule FRET Imaging of Virus Spike-Host Interactions.
Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy.
Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
Expression of SARS-CoV-2 surface glycoprotein fragment 319-640 in E. coli, and its refolding and purification.
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin.
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
Potential neutralizing antibodies discovered for novel corona virus using machine learning.
Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‚ÄëCoV-2 infection.
Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.
Oligomannose 
Sustainability of SARS-CoV-2 Induced Humoral Immune Responses in COVID-19 Patients from Hospitalization to Convalescence Over Six Months.
Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study.
Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques.
Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates.
Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.
Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.
A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.
Emerging Technologies for the Treatment of COVID-19.
A Novel and Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York.
High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19.
Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants.
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies.
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.
Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets.
SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study.
Electrochemical immunosensor with Cu
Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.
Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43.
SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages.
Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population.
VISTA: A Target to Manage the Innate Cytokine Storm.
An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2.
Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses.
Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia.
SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies.
Kinetics of Anti-SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection.
Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans.
Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.
Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.
A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
A Low-Cost SARS-CoV-2 rRBD ELISA to Detect Serostatus in Ecuadorian Population with COVID-19.
Host-directed therapies for COVID-19.
Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant.
Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model.
Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study.
Prolonged evolution of the human B cell response to SARS-CoV-2 infection.
SARS-CoV-2 proteins: Are they useful as targets for COVID-19 drugs and vaccines?
Quantitative Measurement of IgG to Severe Acute Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP.
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.
Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2.
A rapid novel strategy for screening of antibody phage libraries for production, purification, and functional characterization of amber stop codons containing single-chain antibody fragments.
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.
Convalescent plasma for preventing critical illness in COVID-19: A phase 2 trial and immune profile.
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
SARS-CoV-2 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to Campus on Infection Risk Among Community Members.
SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys.
Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization.
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
Rotavirus as an Expression Platform of the SARS-CoV-2 Spike Protein.
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies.
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab 
Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients.
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.
Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection.
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach.
Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor for human CD14
Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors.

The use of dried blood spots for the serological evaluation of SARS-CoV-2 antibodies.
Adaptive immune responses to SARS-CoV-2.
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19.
Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil.
High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.
Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.
Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro.
Rapid Detection of SARS-CoV-2 Antigens Using High-Purity Semiconducting Single-Walled Carbon Nanotube-Based Field-Effect Transistors.
Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677.
Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses.
Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.
Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses.
SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.
Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.
mRNA vaccine: a potential therapeutic strategy.
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.
Anti-spike S1 receptor-binding domain antibodies against SARS-CoV-2 persist several months after infection regardless of disease severity.
Persistence of SARS-CoV-2-specific B and T¬†cell responses in convalescent COVID-19 patients 6-8¬†months after the infection.
Antibody titers against SARS-CoV-2 decline, but do not disappear for several months.
Discrete SARS-CoV-2 antibody titers track with functional humoral stability.
Neutralizing monoclonal antibodies for COVID-19 treatment and prevention.
Making sense of spike D614G in SARS-CoV-2 transmission.
Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a na√Øve human antibody library.
Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without.
Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model.
Treatment and control strategies for COVID-19: Prospects and possibilities.
Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay.
Parameters of immunoglobulin extraction from dried blood spot cards and immunoassays for detection of antibody response to pathogens including the novel SARS-CoV-2.
Avidity assay to test functionality of anti-SARS-Cov-2 antibodies.
Functional alterations caused by mutations reflect evolutionary trends of SARS-CoV-2.
How 'killer' T cells could boost COVID immunity in face of new variants.
Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice.
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.
Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile.
Serological Test to Determine Exposure to SARS-CoV-2: ELISA Based on the Receptor-Binding Domain of the Spike Protein (S-RBD
ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group.
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2¬†S for viral entry.
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.
Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand.
High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation.
Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
Immune response scenario and vaccine development for SARS-CoV-2 infection.
Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.
Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.
In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses.
Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.
Durable SARS-CoV-2 B cell immunity after mild or severe disease.
The allosteric modulation of complement C5 by knob domain peptides.
Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes.
Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature.
In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
The challenge of avidity determination in SARS-CoV-2 serology.
Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant.
Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals.
The basis of a more contagious 501Y.V1 variant of SARS-COV-2.
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.
Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike.
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M‚Ñ¢ vaccination.
Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.
Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia.
Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection.
Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity.
Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.
Variant-proof vaccines - invest now for the next pandemic.
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.
Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers.
SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays.
The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters.
FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein.
Transcriptional and Metabolic Control of Memory B Cells and Plasma Cells.
A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.
Stable neutralizing antibody levels 6¬†months after mild and severe COVID-19 episodes.
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.
Caffeine-Operated Synthetic Modules for Chemogenetic Control of Protein Activities by Life Style.
Peptides-based vaccine against SARS-
Pattern of circulating SARS-CoV-2-specific antibody-secreting and memory B-cell generation in patients with acute COVID-19.
Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals.
A serological survey of severe acute respiratory syndrome coronavirus 2 in dogs in Wuhan.
How glycobiology can help us treat and beat the COVID-19 pandemic.
A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
SARS-CoV-2 evolution during treatment of chronic infection.
Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2.
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice.
A Neutralization Assay Based on Pseudo-Typed Lentivirus with SARS CoV-2 Spike Protein in ACE2-Expressing CRFK Cells.
Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape.
Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Rehabilitation Facility: Evolution of the Presence of Nasopharyngeal SARS-CoV-2 and Serological Antibody Responses.
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
Toolkit for Quickly Generating and Characterizing Molecular Probes Specific for SARS-CoV-2 Nucleocapsid as a Primer for Future Coronavirus Pandemic Preparedness.
Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting.
Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
SARS-CoV-2 recruits a haem metabolite to evade antibody immunity.
Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain.
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes.
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.
A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.
Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail.
Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets.
Modeling mutational effects on biochemical phenotypes using convolutional neural networks: application to SARS-CoV-2.
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.
A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients.
Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2.
SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice.
Presence of antibodies against SARS-CoV-2 spike protein in bovine whey IgG enriched fraction.
Piglet immunization with a spike subunit vaccine enhances disease by porcine epidemic diarrhea virus.
Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein.
BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Retrained Generic Antibodies Can Recognize SARS-CoV-2.
Synthesis and Biopharmaceutical Applications of Sugar-Based Polymers: New Advances and Future Prospects.
Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study.
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.
Comprehensive analysis of T¬†cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.
A high-throughput liquid bead array assay confirms strong correlation between SARS-CoV-2 antibody level and COVID-19 severity.
Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus.
Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol.
Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection.
Development of an Automated Chemiluminescence Assay System for Quantitative Measurement of Multiple Anti-SARS-CoV-2 Antibodies.
Point-of-care test system for detection of immunoglobulin-G and -M against nucleocapsid protein and spike glycoprotein of SARS-CoV-2.
Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.
Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model.
SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.
Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants.
Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia.
Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios.
Biosensors as a future diagnostic approach for COVID-19.
Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration.
Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).
Mutational sensitivity of D614G in spike protein of SARS-CoV-2 in Jordan.
Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals.
De novo design of modular and tunable protein biosensors.
Nicotinic cholinergic system and COVID-19: In silico identification of interactions between Œ±7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins.
The immunodominant and neutralization linear epitopes for SARS-CoV-2.
Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine.
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2.
Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease.
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine.
Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19).
A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection.
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2.
Adaptive immunity to SARS-CoV-2 and COVID-19.
Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.
Distinct antibody repertoires against endemic human coronaviruses in children and adults.
Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam.
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses.
Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters.
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate.
Global absence and targeting of protective immune states in severe COVID-19.
Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis.
ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.
Kidney injury molecule-1 is a potential receptor for SARS-CoV-2.
A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.
SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response.
Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD.
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Antibody persistence in the first 6¬†months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study.
Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics.
Detection of SARS-CoV-2 Viral Particles Using Direct, Reagent-Free Electrochemical Sensing.
Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered 
Fast-spreading COVID variant can elude immune responses.
Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19.
Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape.
Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection.
Flow cytometry multiplexed method for the detection of neutralizing human antibodies to the native SARS-CoV-2 spike protein.
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
Rigid monoclonal antibodies improve detection of SARS-CoV-2 nucleocapsid protein.
CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-2-infected Cells.
SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
Comparison of Antibody Class-Specific SARS-CoV-2 Serologies for the Diagnosis of Acute COVID-19.
Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection.
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.
Mapping and role of T cell response in SARS-CoV-2-infected mice.
Evolution of antibody immunity to SARS-CoV-2.
Improving SARS-CoV-2 structures: Peer review by early coordinate release.
Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity.
Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors.
Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection.
Novel Regeneration Approach for Creating Reusable FO-SPR Probes with NTA Surface Chemistry.
Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.
Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial.
Intravenous Immunoglobulin may Reverse Multisystem Inflammation in COVID-19 Pneumonitis and Guillain-Barr√© Syndrome.
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset.
Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time.
Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina.
Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence.
Fever, Diarrhea, and Severe Disease Correlate with High Persistent Antibody Levels against SARS-CoV-2.
Neuropilin-1 Assists SARS-CoV-2 Infection by Stimulating the Separation of Spike Protein Domains S1 and S2.
The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates.
MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease.
Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates.
Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.
Extracellular vimentin as a target against SARS-CoV-2 host cell invasion.
A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.
Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.
Dual-Antigen System Allows Elimination of False Positive Results in COVID-19 Serological Testing.
SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines.
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
Comparison of the SARS-CoV-2 (2019-nCoV) M protein with its counterparts of SARS-CoV and MERS-CoV species.
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
Generation and Characterization of recombinant SARS-CoV-2 expressing reporter genes.
Rapid SARS-CoV-2 Detection Using Electrochemical Immunosensor.
SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals.
Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.
Pilot Production of SARS-CoV-2 Related Proteins in Plants: A Proof of Concept for Rapid Repurposing of Indoor Farms Into Biomanufacturing Facilities.
Human SARS CoV-2 spike protein mutations.
Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
Cryo-EM analysis of the HCoV-229E spike glycoprotein reveals dynamic prefusion conformational changes.
Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2.
Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins.
COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
Analysis of viral load in different specimen types and serum antibody levels of COVID-19 patients.
Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies.
COVID-19-neutralizing antibodies predict disease severity and survival.
Design, Expression, Purification, and Characterization of a YFP-Tagged 2019-nCoV Spike Receptor-Binding Domain Construct.
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
Cold sensitivity of the SARS-CoV-2 spike ectodomain.
Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review: 31.
Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test.
Kinetics of antibody responses dictate COVID-19 outcome.
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation.
A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.
MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans.
SARS-CoV-2 escape 
Structural basis for broad coronavirus neutralization.
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma.
Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions.
Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray.
Stereotypic neutralizing V
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.
Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.
Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.
CRISPR-based strategies in infectious disease diagnosis and therapy.
Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?
A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters.
Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.
Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Differential serological and neutralizing antibody dynamics after an infection by a single SARS-CoV-2 strain.
Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures.
Audio Interview: A Look at Covid-19 Prevention and Care in 2020.
A New Crystal Form of the SARS-CoV-2 Receptor Binding Domain: CR3022 Complex-An Ideal Target for In-Crystal Fragment Screening of the ACE2 Binding Site Surface.
Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants.
Comparison of Four SARS-CoV-2 Neutralization Assays.
Structure and immune recognition of the porcine epidemic diarrhea virus spike protein.
The development of neutralizing antibodies against SARS-CoV-2 and their common features.
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Do Animals Play a Role in the Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)? A Commentary.
A porcine epidemic diarrhea virus strain with distinct characteristics of four amino acid insertion in the COE region of spike protein.
SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution.
Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2.
SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.
Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates.
Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection.
High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms.
Multiplex bead binding assays using off-the-shelf components and common flow cytometers.
Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review.
Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.
Tocilizumab in the Management of COVID-19: A Preliminary Report.
Paper-based electrochemical biosensor for diagnosing COVID-19: Detection of SARS-CoV-2 antibodies and antigen.
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.
High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.
Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA.
Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality.
Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic.
Sensing of COVID-19 Antibodies in Seconds via Aerosol Jet Nanoprinted Reduced-Graphene-Oxide-Coated 3D Electrodes.
Neutralizing antibodies targeting SARS-CoV-2 spike protein.
Infectious bronchitis virus: Identification of Gallus gallus APN high-affinity ligands with antiviral effects.
CD147 as an alternative binding site for the spike protein on the surface of SARS-CoV-2.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
Comparative molecular dynamics study of the receptor-binding domains in SARS-CoV-2 and SARS-CoV and the effects of mutations on the binding affinity.
IgG Antibodies against SARS-CoV-2 Correlate with Days from Symptom Onset, Viral Load and IL-10.
Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials.
Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif.
Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.
Monoclonal Antibodies B38 and H4 Produced in 
Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report.
A single dose of recombinant VSV-‚àÜG-spike vaccine provides protection against SARS-CoV-2 challenge.
An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs.
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
Neutralizing SARS-CoV-2.
A high-throughput multiplexed microfluidic device for COVID-19 serology assays.
Immunologic Testing for SARS-CoV-2 Infection from the Antigen Perspective.
Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study.
6-month SARS-CoV-2 antibody persistency in a¬†Tyrolian COVID-19 cohort.
Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells.
The kinetics of humoral response and its relationship with the disease severity in COVID-19.
Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects.
Dynamic anti-spike protein antibody profiles in COVID-19 patients.
The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition.
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.
Structural assessment of SARS-CoV2 accessory protein ORF7a predicts LFA-1 and Mac-1 binding potential.
Multicenter Evaluation of the Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of 10 High-Throughput Serological Assays Used in Clinical Laboratories.
COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.
Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection.
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.
Risk Factors of SARS-CoV-2 Antibodies in Arapahoe County First Responders-The COVID-19 Arapahoe SErosurveillance Study (CASES) Project.
The Role of Interleukin-6 in the Pathogenesis, Prognosis and Treatment of Severe COVID-19.
Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals.
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.
Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients.
Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.
SSSCPreds: Deep Neural Network-Based Software for the Prediction of Conformational Variability and Application to SARS-CoV-2.
Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis.
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.
Deletion in the S1 Region of Porcine Epidemic Diarrhea Virus Reduces the Virulence and Influences the Virus-Neutralizing Activity of the Antibody Induced.
Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.
Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins.
Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2.
Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains.
Non-Receptor-Mediated Lipid Membrane Permeabilization by the SARS-CoV-2 Spike Protein S1 Subunit.
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Therapeutic targeting of interleukin-6 for the treatment of COVID-19.
Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens.
T cell and antibody functional correlates of severe COVID-19.
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry 
Characterization of SARS-CoV-2 N protein reveals multiple functional consequences of the C-terminal domain.
Identification of HLA-A*02:01-restricted candidate epitopes derived from the non-structural polyprotein 1a of SARS-CoV-2 that may be natural targets of CD8
Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review).
Structure-based development of human antibody cocktails against SARS-CoV-2.
Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection.
Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study.
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.
Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens.
Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity.
Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.
A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine.
A role of glycation and methylation for SARS-CoV-2 infection in diabetes?
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control.
Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Reactive Antibodies: December 2019-January 2020.
Nanomedicinal delivery of stimulator of¬†interferon genes agonists: recent advances in virus vaccination.
Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach.
Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays.
SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein.
HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry.
Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody.
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity.
Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles.
Convalescent Memory T Cell Immunity in Individuals with Mild or Asymptomatic SARS-CoV-2 Infection May Result from an Evolutionarily Adapted Immune Response to Coronavirus and the 'Common Cold'.
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.
Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera.
Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure.
Dysregulated immunity in SARS-CoV-2 infected pregnant women.
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
The Development of a Novel Nanobody Therapeutic for SARS-CoV-2.
High resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19.
TAM receptors: A phosphatidylserine receptor family and its implications in viral infections.
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.
Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.
Recombinant vaccines for COVID-19.
Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate.
Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study.
Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.
Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis.
Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can Play a Preventive Role Against Viral Diseases Including COVID-19.
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19.
Antibody profiling and prevalence in US patients during the SARS-CoV2 pandemic.
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19.
SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals.
Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.
Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins.
Quantitative measurement of IgG to SARS-CoV-2 proteins using ImmunoCAP.
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.
Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization.
Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals.
The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design.
Immunodominant regions prediction of nucleocapsid protein for SARS-CoV-2 early diagnosis: a bioinformatics and immunoinformatics study.
Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening.
Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?
ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives.
CoVaccine HT‚Ñ¢ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization.
Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology.
Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals.
Multi-species ELISA for the detection of antibodies against SARS-CoV-2 in animals.
Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2.
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity.
Spike Glycoprotein-Mediated Entry of SARS Coronaviruses.
Structural basis of severe acute respiratory syndrome coronavirus 2 infection.
Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2.
Characterization of pre-existing and induced SARS-CoV-2-specific CD8
Neutralizing monoclonal antibody fails to recognize porcine epidemic diarrhea virus with two regions deleted in spike protein.
Immunological Assessment of Pediatric Multisystem Inflammatory Syndrome Related to Coronavirus Disease 2019.
COVID-19 in the Developing World: Is the Immune Response to Œ±-Gal an Overlooked Factor Mitigating the Severity of Infection?
Treatment With Tocilizumab for Patients With COVID-19 Infections: A Case-Series Study.
Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19.
Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy.
Neurological manifestations of coronavirus infections: role of angiotensin-converting enzyme 2 in COVID-19.
SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up.
Multiplexed, quantitative serological profiling of COVID-19 from a drop of blood by a point-of-care test.
Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2.
The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition.
Evolution of Antibody Immunity to SARS-CoV-2.
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice.
A Hydrophobic-Interaction-Based Mechanism Triggers Docking between the SARS-CoV-2 Spike and Angiotensin-Converting Enzyme 2.
The PentaFOLD 3.0 Algorithm for the Selection of Stable Elements of Secondary Structure to be Included in Vaccine Peptides.
Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications.
Kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19: a descriptive study.
Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020.
Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches.
A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children.
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview.
COVID-19 update: The race to therapeutic development.
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.
Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation.
Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG.
Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility.
Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum.
Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein.
Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment.
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.
Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta-analysis.
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.
SARS-CoV-2 Cysteine-like Protease Antibodies Can Be Detected in Serum and Saliva of COVID-19-Seropositive Individuals.

Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies.
Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain.
Peptide Inhibitors of the Œ±-Cobratoxin-Nicotinic Acetylcholine Receptor Interaction.
The Role of Molecular Chaperones in Virus Infection and Implications for Understanding and Treating COVID-19.
Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.
Durable SARS-CoV-2 B cell immunity after mild or severe disease.
A cell-free antibody engineering platform rapidly generates SARS-CoV-2 neutralizing antibodies.
Global Absence and Targeting of Protective Immune States in Severe COVID-19.
Global Absence and Targeting of Protective Immune States in Severe COVID-19.
Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein.
Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.
Conjugation of Human Œ≤-Defensin 2 to Spike Protein Receptor-Binding Domain Induces Antigen-Specific Protective Immunity against Middle East Respiratory Syndrome Coronavirus Infection in Human Dipeptidyl Peptidase 4 Transgenic Mice.
Anti-S1 MERS-COV IgY Specific Antibodies Decreases Lung Inflammation and Viral Antigen Positive Cells in the Human Transgenic Mouse Model.
Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.
A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.
Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID-19.
Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk.
Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
Virological and Serological Discordant Profiles in COVID-19 Pneumonia: Two Atypical Clinical Cases.
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.
Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19.
Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.
Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates.
High Rate of Circulating MERS-CoV in Dromedary Camels at Slaughterhouses in Riyadh, 2019.
A SARS-CoV-2 variant with the 12-bp deletion at E gene.
An Effective COVID-19 Vaccine Needs to Engage T Cells.
The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens.
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization.
Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease.
COVID-19, varying genetic resistance to viral disease and immune tolerance checkpoints.
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations.
SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
Antibody Binding Epitope Mapping (AbMap) of Hundred Antibodies in a Single Run.
COVID-19 neutralizing antibodies predict disease severity and survival.
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.
Spike mutation D614G alters SARS-CoV-2 fitness.
Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
Change of Antigenic Determinants of SARS-CoV-2 Virus S-Protein as a Possible Cause of Antibody-Dependent Enhancement of Virus Infection and Cytokine Storm.
COVID-19 Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus.
An Overview of the Crystallized Structures of the SARS-CoV-2.
A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone.
Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19.
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays.
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.
Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein.
Rabies virus-based COVID-19 vaccine CORAVAX‚Ñ¢ induces high levels of neutralizing antibodies against SARS-CoV-2.
Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein.
The bumpy road to achieve herd immunity in COVID-19.
Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.
Deep mutagenesis in the study of COVID-19: a technical overview for the proteomics community.
Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset.
The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
Ongoing Global and Regional Adaptive Evolution of SARS-CoV-2.
Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies.
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.
Neuropilin-1 is a host factor for SARS-CoV-2 infection.
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.
Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
Rapid detection of SARS-CoV-2 antibodies using electrochemical impedance-based detector.
Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severity.
Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions.
Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome.
Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19.
Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform.
Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies.
NCAM protein and SARS-COV-2 surface proteins: In-silico hypothetical evidence for the immunopathogenesis of Guillain-Barr√© syndrome.
Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.
COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva.
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection.
SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19.
Review of COVID-19 Antibody Therapies.
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Unique immunological profile in patients with COVID-19.
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
What are protective antibody responses to pandemic SARS-CoV-2?
Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.
Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19.
A multiplex microsphere IgG assay for SARS-CoV-2 using ACE2-mediated inhibition as a surrogate for neutralization.
Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice.
The landscape of antibody binding in SARS-CoV-2 infection.
CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation.
Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors.
A systematic review of SARS-CoV-2 vaccine candidates.
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Validation and clinical evaluation of a SARS-CoV-2‚ÄÖsurrogate virus neutralisation test (sVNT).
Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective.
Plant-Derived Trimeric CO-26K-Equivalent Epitope Induced Neutralizing Antibodies Against Porcine Epidemic Diarrhea Virus.
Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions.
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract.
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.
Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.
Drug screening and development from the affinity of S protein of new coronavirus with ACE2.
Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses.
Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh.

Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study.
Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors.
An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain.
An approach to lifting self-isolation for health care workers with prolonged shedding of SARS-CoV-2 RNA.
Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.
Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2.
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.
Development of an antibody-dependent cellular cytotoxicity reporter assay for measuring anti-Middle East Respiratory Syndrome antibody bioactivity.
Persistence of Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers.
Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike.
Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNAR
Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay.
Epidemiology, Genomic Structure, the Molecular Mechanism of Injury, Diagnosis and Clinical Manifestations of Coronavirus Infection: An Overview.
Antiviral therapies: advances and perspectives.
Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting.
Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development.
Designing a multi-epitope peptide based vaccine against SARS-CoV-2.
Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset.
Development and Optimization of In-house ELISA for Detection of Human IgG Antibody to SARS-CoV-2 Full Length Spike Protein.
COVID-19 vaccine BNT162b1 elicits human antibody and T
Accuracy of serological testing for SARS-CoV-2 antibodies: First results of a large mixed-method evaluation study.
COVID-19 and human milk: SARS-CoV-2, antibodies, and neutralizing capacity.
KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney.
AI-guided discovery of the invariant host response to viral pandemics.
A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.
Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model.
Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.
The flexibility of ACE2 in the context of SARS-CoV-2 infection.
Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2.
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.
Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats.
Porcine deltacoronavirus nucleocapsid protein species-specifically suppressed IRF7-induced type I interferon production via ubiquitin-proteasomal degradation pathway.
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain.
Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.
Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays.
Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs.
Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2.
Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study.
Structural and functional modelling of SARS-CoV-2 entry in animal models.
Immunotherapy approaches on innate immunity for SARS-Cov-2.
What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.
SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus.
High-throughput viral microneutralization method for feline coronavirus using image cytometry.
The complexities of SARS-CoV-2 serology.
SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys.
S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
Middle East respiratory coronavirus (MERS-CoV) spike (S) protein vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable alternative to the conventional neutralization assay in human seroepidemiological studies.
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings.
Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals.
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system.
Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.
Understanding the Role of Corona Virus based on Current Scientific Evidence - A Review with Emerging Importance in Pandemic.
Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease.
Collaborative networks enable the rapid establishment of serological assays for SARS-CoV-2 during nationwide lockdown in New Zealand.
Carbohydrate-Binding Agents: Potential of Repurposing for COVID-19 Therapy.
Targeting multiple epitopes on the spike protein: a new hope for COVID-19 antibody therapy.
Efficacy of convalescent plasma according to blood groups in COVID-19 patients
Antibody-like proteins that capture and neutralize SARS-CoV-2.
Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein.
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
Impact of Circulating SARS-CoV-2 Mutant G614 on the COVID-19 Pandemic.
Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.
High Potency of a Bivalent Human V
Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2.
Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.
Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia.
Immunity against SARS-CoV-2: walking to the vaccination.
Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition.
Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles.
SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike.
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility.
Striking Similarities between CDRs in Some mAbs That Neutralize COVID-19.
Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as "Achilles' Heel" of Viruses Contributing to Anti-Viral Immune Protection.
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease.
Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition.
Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays.
New insights on possible vaccine development against SARS-CoV-2.
Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma.
The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector.
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds.
Improved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based Antibody Assay.
COVID-19 and the Path to Immunity.
Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike.
A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients.
Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.
Observational study on off-label use of tocilizumab in patients with severe COVID-19.
Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip.
Snatching the Crown from SARS-CoV-2.
Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.
SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2.
Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration.
Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies.
Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction.
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility.
Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present Œ±-gal epitopes.
Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.
Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters.
Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.
Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability.
SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology's Headache Study Group.
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.
Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells.
Kinetics of Viral Clearance and Antibody Production Across Age Groups in Children with Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
CoV3D: a database of high resolution coronavirus protein structures.
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19.
Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals.
The Answer Lies in the Energy: How Simple Atomistic Molecular Dynamics Simulations May Hold the Key to Epitope Prediction on the Fully Glycosylated SARS-CoV-2 Spike Protein.
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.
Future perspective: biologic agents in patients with severe COVID-19.
SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.
Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication.
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?
Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk.
Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?
Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
Immunocytometric analysis of COVID patients: A contribution to personalized therapy?
A simple protein-based surrogate neutralization assay for SARS-CoV-2.
Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2.
A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice.
Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies.
Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis.
A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants.
A serological survey of SARS-CoV-2 in cat in Wuhan.
Comparative evaluation of SARS-CoV-2 IgG assays in India.
Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test 
Age-Related Differences in Immunological Responses to SARS-CoV-2.
A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2.
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.
SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients.
Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19.
A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment.
Functional Pangenome Analysis Shows Key Features of E Protein Are Preserved in SARS and SARS-CoV-2.
Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung.
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.
Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis.
Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.
Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.
Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.
Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial.
SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness.
Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community.
Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2.
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.
Immunoinformatics characterization of SARS-CoV-2 spike glycoprotein for prioritization of epitope based multivalent peptide vaccine.
Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.
Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Polymonoclonal (Not Polyclonal) Antibodies Derived from Convalescent Human B Cell Hybridomas Might Be a Better Therapeutic Option than Single Target Monoclonal Antibodies.
The use of knowledge management tools in viroinformatics. Example study of a highly conserved sequence motif in Nsp3 of SARS-CoV-2 as a therapeutic target.
Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.
Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses.
A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.
SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.
Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach.
Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure.
A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model.
A 3.4-√Ö cryo-EM structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles.
Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells.
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2.
An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation.
Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice.
Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS.
A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency Use.
Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates¬†heterogeneity.
Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Structures and distributions of SARS-CoV-2 spike proteins on intact virions.
CoV-AbDab: the coronavirus antibody database.
A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.
Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.
Anti-SARS-CoV-2 spike antibodies are stable in convalescent plasma when stored at 4¬∞ Celsius for at least 6‚Äâweeks.
Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay.
Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses.
High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay.
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19.
False-positive SARS-CoV-2 serology in 3 children with Kawasaki disease.
Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.
A Thermostable mRNA Vaccine against COVID-19.
Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents.
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity.
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.
Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19.
Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes.
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.
Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Structure of Furin Protease Binding to SARS-CoV-2 Spike Glycoprotein and Implications for Potential Targets and Virulence.
Phase¬†I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Russia's fast-track coronavirus vaccine draws outrage over safety.
The role of IgG Fc receptors in antibody-dependent enhancement.
Atomistic simulation reveals structural mechanisms underlying D614G spike glycoprotein-enhanced fitness in SARS-COV-2.
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
Immune monitoring facilitates the clinical decision in multifocal COVID-19 of a pancreas-kidney transplant patient.
Increased Complement Receptor-3 levels in monocytes and granulocytes distinguish COVID-19 patients with pneumonia from those with mild symptoms.
Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2.
Strategies and perspectives to develop SARS-CoV-2 detection methods and diagnostics.
Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence.
Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2.
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
Heat Shock Protein Member 8 Is an Attachment Factor for Infectious Bronchitis Virus.
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm.
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.
Why do children seem to be more protected against COVID-19? A hypothesis.
Comparative analysis of structural characteristics and epitopes in S proteins between SARS-CoV-2 and SARS-CoV.
Detection of SARS-CoV-2 by RNAscope
Fast-and-fit vaccines.
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.
Rethinking interleukin-6 blockade for treatment of COVID-19.
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic.
Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19.
Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation.
Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients.
Cross-Comparison of a Chemiluminescent Platform and a Commercial Receptor Binding Domain-Based ELISA‚ÄÇfor Detecting SARS-CoV-2 IgG.
Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
Orientation of immobilized antigens on common surfaces by a simple computational model: Exposition of SARS-CoV-2 Spike protein RBD epitopes.
Dynamics and significance of the antibody response to SARS-CoV-2 infection.
Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological Sex.
CoVaccine HT‚Ñ¢ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation.
The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State.
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain.
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate.
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV.
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2.
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.
An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.
A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
Tumor markers as an entry for SARS-CoV-2 infection?
Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases.
A thermostable, closed SARS-CoV-2 spike protein trimer.
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial.
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.
Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding.
SARS-CoV-2: A Piece of Bad News.
Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach.
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.
SARS-CoV-2 seroprevalence among parturient women in Philadelphia.
Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a na√Øve semisynthetic library.
Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
Developing a low-cost and accessible COVID-19 vaccine for global health.
Interaction of HSPA5 (Grp78, BIP) with negatively charged phospholipid membranes via oligomerization involving the N-terminal end domain.
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.
COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis.
Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections.
The virology of SARS-CoV-2.
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.
Promise and challenges in the development of COVID-19 vaccines.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19.
Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization.
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
Pharmaco-Immunomodulatory Therapy in COVID-19.
Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.
Coronavirus vaccines get a biotech boost.
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
An 
Oncology-Inspired Treatment Options for COVID-19.
Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes.
Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19.
Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis.
Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2.
EMMPRIN/BASIGIN as a biological modulator of oral cancer and COVID-19 interaction: Novel propositions.
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.
SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses.
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19.
Structural basis of a shared antibody response to SARS-CoV-2.
Immunoglobulin fragment F(ab')
Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.
Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.
Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein.
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.
Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery.
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.
Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.
Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Critical Sequence Hot-spots for Binding of nCOV-2019 to ACE2 as Evaluated by Molecular Simulations.
Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation.
Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains.
A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies.
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
Feline infectious peritonitis virus-associated rhinitis in a cat.
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment.
Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections.
Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient.
Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review.
Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus 
Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
Basic principles of replication and immunology of SARS-CoV-2.
Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients.
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.
SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients.
Humoral immune responses in piglets experimentally infected with a field strain of porcine epidemic diarrhea virus.
Validation of a commercially available SARS-CoV-2 serological immunoassay.
Review of COVID-19 Antibody Therapies.
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.
SARS-CoV-2 neutralizing antibody development strategies.
COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
Targeting adenosinergic pathway and adenosine A
Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike.
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding.
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Does Early Childhood Vaccination Protect Against COVID-19?
Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.
Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively.
Limited Cross-Protection against Infectious Bronchitis Provided by Recombinant Infectious Bronchitis Viruses Expressing Heterologous Spike Glycoproteins.
In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies.
Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay.
Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay.
Broad and strong memory CD4 
Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 
CoV3D: A database and resource for high resolution coronavirus protein structures.
Development and validation of IMMUNO-COV‚Ñ¢: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2.
Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies.
Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein.
Structural basis of a public antibody response to SARS-CoV-2.
Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike.
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on page 486.
Structural Basis of SARS-CoV-2- and SARS-CoV-Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.
Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.
Molecular Diagnosis of COVID-19: Challenges and Research Needs.
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Molecular Targets in the Chemotherapy of Coronavirus Infection.
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Perspectives on the development of neutralizing antibodies against SARS-CoV-2.
Virus-like particle vaccine with B-cell epitope from porcine epidemic diarrhea virus (PEDV) incorporated into hepatitis B virus core capsid provides clinical alleviation against PEDV in neonatal piglets through lactogenic immunity.
Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.
A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
COVID-19 revisiting inflammatory pathways of arthritis.
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.
Critical Differences between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV.
Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold.
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
Broad neutralization of SARS-related viruses by human monoclonal antibodies.
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series.
Monoclonal Antibodies for Prevention and Treatment of COVID-19.
Passive antibody therapy in COVID-19.
Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
Immunoinformatics and Structural Analysis for Identification of Immunodominant Epitopes in SARS-CoV-2 as Potential Vaccine Targets.
IgA Summons IgG to Take a Hit at HIV-1.
Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics.
Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.
In¬†vitro diagnostics of coronavirus disease 2019: Technologies and application.
Neutralizing antibodies mediate virus-immune pathology of COVID-19.
An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
A High Through-put Assay for Circulating Antibodies Directed against the S Protein of Severe Acute Respiratory Syndrome Corona virus 2.
The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies.
Rapid generation of neutralizing antibody responses in COVID-19 patients.
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva.
A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding.
Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates.
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models.
Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals.
Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.
IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity.
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model.
Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement.
Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.
Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein.
Structural and functional analysis of a potent sarbecovirus neutralizing antibody.
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.
Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein.
Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.
Analysis of the SARS-CoV-2 spike protein glycan shield: implications for immune recognition.
A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein.
Novel Immunoglobulin Domain Proteins Provide Insights into Evolution and Pathogenesis Mechanisms of SARS-Related Coronaviruses.
Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation.
A new and rapid approach for detecting COVID-19 based on S1 protein fragments.
Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.
Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions.
Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
An off-the-Shelf Approach for the Production of Fc Fusion Proteins by Protein 
Genomic Sequencing and Analysis of Eight Camel-Derived Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Isolates in Saudi Arabia.
A novel luciferase immunosorbent assay performs better than a commercial enzyme-linked immunosorbent assay to detect MERS-CoV specific IgG in humans and animals.
First detection and genome sequencing of SARS-CoV-2 in an infected cat in France.
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Novel Immunoglobulin Domain Proteins Provide Insights into Evolution and Pathogenesis of SARS-CoV-2-Related Viruses.
Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV.
The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation.
COVID-19: Gene Transfer to the Rescue?
Human neutralizing antibodies elicited by SARS-CoV-2 infection.
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Immunization with porcine epidemic diarrhea virus harbouring Fc domain of IgG enhances antibody production in pigs.
Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines.
Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.
SARS-CoV-2 infection protects against rechallenge in rhesus macaques.
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Immunogenicity of a DNA vaccine candidate for COVID-19.
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Molecular Targets for the Testing of COVID-19.
High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19.
Glycyrrhetinic acid alleviates hepatic inflammation injury in viral hepatitis disease via a HMGB1-TLR4 signaling pathway.
On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.
Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
A spike with which to beat COVID-19?
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
Identification of Human Single-Domain Antibodies against SARS-CoV-2.
Androgen sensitivity gateway to COVID-19 disease severity.
Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.
SARS-CoV-2: A New Song Recalls an Old Melody.
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.
Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.
SARS-CoV-2 immunogenicity at the crossroads.
MERS-CoV Spike Protein Vaccine and Inactivated Influenza Vaccine Formulated with Single Strand RNA Adjuvant Induce T-Cell Activation through Intranasal Immunization in Mice.
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Recent advances of therapeutic targets and potential drugs of COVID-19.
A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.
Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control.
Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.
Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of¬†Middle East respiratory syndrome coronavirus.
Perspectives of Immune Therapy in Coronavirus Disease 2019.
Protective humoral immunity in SARS-CoV-2 infected pediatric patients.
Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.
Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins.
Convalescent plasma in Covid-19: Possible mechanisms of action.
Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.
Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein.
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate.
The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections.
A human monoclonal antibody blocking SARS-CoV-2 infection.
Forecasting the timeframe of 2019-nCoV and human cells interaction with reverse engineering.
Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment.
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.
Connecting clusters of COVID-19: an epidemiological and serological investigation.
Translating IL-6 biology into effective treatments.
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
A short review on antibody therapy for COVID-19.
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.
On the molecular determinants of the SARS-CoV-2 attack.
Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends.
Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2.
SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup.
Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures.
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.
Built-in RNA-mediated chaperone (chaperna) for antigen folding tailored to immunized hosts.
The Science Underlying COVID-19: Implications for the Cardiovascular System.
Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
Field trials evaluating the efficacy of porcine epidemic diarrhea vaccine, RNA (Harrisvaccine) in the Philippines.
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.
Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles.
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients.
Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.
QTY Code-designed Water-soluble Fc-fusion Cytokine Receptors Bind to their Respective Ligands.
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2?
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.
Identification of a novel B-cell epitope in the spike protein of porcine epidemic diarrhea virus.
Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.
Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility.
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020.
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.
A Computational Vaccine Designing Approach for MERS-CoV Infections.
Harnessing the immune system via FcŒ≥R function in immune therapy: a pathway to next-gen mAbs.
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies.
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Attenuated porcine-derived type 2 bovine viral diarrhea virus as vector stably expressing viral gene.
Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Efficacy of orally administered porcine epidemic diarrhea vaccine-loaded hydroxypropyl methylcellulose phthalate microspheres and RANKL-secreting L. lactis.
Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
Structure analysis of the receptor binding of 2019-nCoV.
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus.
Development of an indirect ELISA for detecting porcine deltacoronavirus IgA antibodies.
Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China.
An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.
Regulation of Immunity-Related Genes by Infectious Bronchitis Virus Challenge in Spleen of Laying Chickens.
Middle East Respiratory Syndrome Coronavirus Antibodies in Bactrian and Hybrid Camels from Dubai.
Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice.
Identification of a Novel Linear B-Cell Epitope on the Nucleocapsid Protein of Porcine Deltacoronavirus.
Recombinant adenovirus carrying a core neutralizing epitope of porcine epidemic diarrhea virus and heat-labile enterotoxin B of Escherichia coli as a mucosal vaccine.
Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein.
Adaptive immunity to SARS-CoV-2.
Viral Proteins under 70 Kilodaltons in Size Prevent the Development of Long-Lasting B-Cell Immune Memory and IgG2a Prevention in COVID-19 Vaccines.
Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA.
Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.
Crystallization and Structural Determination of the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein.
Recombinant adenoviral vaccine encoding the spike 1 subunit of the 
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.
Identification of the immunodominant neutralizing regions in the spike glycoprotein of porcine deltacoronavirus.
A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice.
Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection.
Development and Validation of a S1 Protein-Based ELISA for the Specific Detection of Antibodies against Equine Coronavirus.
Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018.
Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein.
Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels.
A Minimally Replicative Vaccine Protects Vaccinated Piglets Against Challenge With the Porcine Epidemic Diarrhea Virus.
Evaluation of serological assays available in a biosafety level 2 laboratory and their application for survey of Middle East respiratory syndrome coronavirus among livestock in Ethiopia.
The S2 Subunit of QX-type Infectious Bronchitis Coronavirus Spike Protein Is an Essential Determinant of Neurotropism.
Serological evidence of MERS-CoV and HKU8-related CoV co-infection in Kenyan camels.
Generation of a Nebulizable CDR-Modified MERS-CoV Neutralizing Human Antibody.
Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
Integrin Œ±vŒ≤3 enhances replication of porcine epidemic diarrhea virus on Vero E6 and porcine intestinal epithelial cells.
Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD.
Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning.
Pathogenicity of porcine deltacoronavirus (PDCoV) strain NH and immunization of pregnant sows with an inactivated PDCoV vaccine protects 5-day-old neonatal piglets from virulent challenge.
Diversity of Dromedary Camel Coronavirus HKU23 in African Camels Revealed Multiple Recombination Events among Closely Related Betacoronaviruses of the Subgenus Embecovirus.
Detection of MERS-CoV antigen on formalin-fixed paraffin-embedded nasal tissue of alpacas by immunohistochemistry using human monoclonal antibodies directed against different epitopes of the spike protein.
Peptides with 16R in S2 protein showed broad reactions with sera against different types of infectious bronchitis viruses.
Specific recombinant proteins of porcine epidemic diarrhea virus are immunogenic, revealing their potential use as diagnostic markers.
Porcine IL-12 plasmid as an adjuvant improves the cellular and humoral immune responses of DNA vaccine targeting transmissible gastroenteritis virus spike gene in a mouse model.
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice.
Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections.
Serological Screening for Coronavirus Infections in Cats.
Recombinant Chimeric Transmissible Gastroenteritis Virus (TGEV) - Porcine Epidemic Diarrhea Virus (PEDV) Virus Provides Protection against Virulent PEDV.
Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein.
Upregulation of CD4
Middle East Respiratory Syndrome Coronavirus in Dromedaries in Ethiopia Is Antigenically Different From the Middle East Isolate EMC.
Antibody-mediated protection against MERS-CoV in the murine model.
Bacterial Outer Membrane Vesicles (OMVs)-based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV.
Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection.
Recombinant vesicular stomatitis virus expressing the spike protein of genotype 2b porcine epidemic diarrhea virus: A platform for vaccine development against emerging epidemic isolates.
Molecular characterization of a Korean porcine epidemic diarrhea virus strain NB1.
Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development.
Differential recognition of peptides within feline coronavirus polyprotein 1 ab by sera from healthy cats and cats with feline infectious peritonitis.
Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein.
Protection conferred by a vaccine derived from an inactivated Egyptian variant of infectious bronchitis virus: a challenge experiment.
Nucleotide Sequence Analysis of S1 Gene among Iranian Avian Infectious Bronchitis Viruses Isolated during 2001-2002.
Effect of Fc Fusion on Folding and Immunogenicity of Middle East Respiratory Syndrome Coronavirus Spike Protein.
Identification of a novel linear B-cell epitope within the collagenase equivalent domain of porcine epidemic diarrhea virus spike glycoprotein.
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein.
A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.
Sequential Emergence and Wide Spread of Neutralization Escape Middle East Respiratory Syndrome Coronavirus Mutants, South Korea, 2015.
Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia.
Identification and characterization of a novel linear epitope in the spike protein of the porcine epidemic diarrhea virus.
Generation, identification, and functional analysis of monoclonal antibodies against porcine epidemic diarrhea virus nucleocapsid.
Construction of a Recombinant Lactococcus lactis Strain Expressing a Variant Porcine Epidemic Diarrhea Virus S1 Gene and Its Immunogenicity Analysis in Mice.
Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas.
Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.
Identification of Neutralizing Monoclonal Antibodies Targeting Novel Conformational Epitopes of the Porcine Epidemic Diarrhoea Virus Spike Protein.
Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain.
Construction and characterization of porcine single-chain fragment variable antibodies that neutralize transmissible gastroenteritis virus in vitro.
Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion.
Structure-Based Vaccine Antigen Design.
Development and validation of different indirect ELISAs for MERS-CoV serological testing.
Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism.
Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain.
Single Chain Fragment Variable (scFv) Antibodies Targeting the Spike Protein of Porcine Epidemic Diarrhea Virus Provide Protection against Viral Infection in Piglets.
Evaluation on the efficacy and immunogenicity of recombinant DNA plasmids expressing S gene from porcine epidemic diarrhea virus and VP7 gene from porcine rotavirus.
Construction and next-generation sequencing analysis of a large phage-displayed V
Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD.
Alterations in sialic-acid O-acetylation glycoforms during murine erythrocyte development.
Production of a Monoclonal Antibody Targeting the M Protein of MERS-CoV for Detection of MERS-CoV Using a Synthetic Peptide Epitope Formulated with a CpG-DNA-Liposome Complex.
CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice.
Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.
Virus neutralization study using H120, H52, 793/B antisera against Iranian infectious bronchitis virus genotypes.
A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry.
Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization.
Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus.
Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex.
A newly isolated Chinese virulent genotype GIIb porcine epidemic diarrhea virus strain: Biological characteristics, pathogenicity and immune protective effects as an inactivated vaccine candidate.
Neutralizing antibodies against porcine epidemic diarrhea virus block virus attachment and internalization.
Single-domain antibodies as promising experimental tools in imaging and isolation of porcine epidemic diarrhea virus.
A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV.
Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus.
Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection.
A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV.
Human Œ≤-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity.
Prospects for a MERS-CoV spike vaccine.
Immune response characterization of mice immunized with Lactobacillus plantarum expressing spike antigen of transmissible gastroenteritis virus.
Immune responses induced by recombinant Lactobacillus plantarum expressing the spike protein derived from transmissible gastroenteritis virus in piglets.
Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein.
Porcine epidemic diarrhea vaccine evaluation using a newly isolated strain from Korea.
Efficacy of heat-labile enterotoxin B subunit-adjuvanted parenteral porcine epidemic diarrhea virus trimeric spike subunit vaccine in piglets.
Display of Porcine Epidemic Diarrhea Virus Spike Protein on Baculovirus to Improve Immunogenicity and Protective Efficacy.
A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Identification of Novel Linear Epitopes Located in the Infectious Bronchitis Virus Spike S2 Region.
Epitope selection and their placement for increased virus neutralization in a novel vaccination strategy for porcine epidemic diarrhea virus utilizing the Hepatitis B virus core antigen.
Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model.
Development of sandwich Enzyme-Linked Immunosorbent Assay for the detection of porcine epidemic diarrhea virus in fecal samples.
Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles.
Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient.
Discovery and Sequence Analysis of Four Deltacoronaviruses from Birds in the Middle East Reveal Interspecies Jumping with Recombination as a Potential Mechanism for Avian-to-Avian and Avian-to-Mammalian Transmission.
Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility.
Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
Passive immunity to porcine epidemic diarrhea virus following immunization of pregnant gilts with a recombinant orf virus vector expressing the spike protein.
Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV.
Sero-prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) specific antibodies in dromedary camels in Tabuk, Saudi Arabia.
Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus.
Using thermodynamic parameters to calibrate a mechanistic dose-response for infection of a host by a virus.
Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen.
PED subunit vaccine based on COE domain replacement of flagellin domain D3 improved specific humoral and mucosal immunity in mice.
Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus.
Construction and identification of nanobody phage display library targeting Middle East respiratory syndrome coronavirus.
Molecular epidemiological study of human coronavirus OC43 in Shanghai from 2009-2016.
Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection.
Construction and immunogenicity analysis of Lactobacillus plantarum expressing a porcine epidemic diarrhea virus S gene fused to a DC-targeting peptide.
A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization.
Identification of a peptide derived from the heptad repeat 2 region of the porcine epidemic diarrhea virus (PEDV) spike glycoprotein that is capable of suppressing PEDV entry and inducing neutralizing antibodies.
Oral immunization with a Lactobacillus casei-based anti-porcine epidemic diarrhoea virus (PEDV) vaccine expressing microfold cell-targeting peptide Co1 fused with the COE antigen of PEDV.
Receptor-binding loops in alphacoronavirus adaptation and evolution.
Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses.
Hepatitis B core antigen based novel vaccine against porcine epidemic diarrhea virus.
Cell attenuated porcine epidemic diarrhea virus strain Zhejiang08 provides effective immune protection attributed to dendritic cell stimulation.
Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric Infections.
Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion.
Oral Delivery of Probiotics Expressing Dendritic Cell-Targeting Peptide Fused with Porcine Epidemic Diarrhea Virus COE Antigen: A Promising Vaccine Strategy against PEDV.
Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA.
The bulky and the sweet: How neutralizing antibodies and glycan receptors compete for virus binding.
Cross protective immune responses in nursing piglets infected with a US spike-insertion deletion porcine epidemic diarrhea virus strain and challenged with an original US PEDV strain.
Immunogenicity of eGFP-Marked Recombinant Lactobacillus casei against Transmissible Gastroenteritis Virus and Porcine Epidemic Diarrhea Virus.
Protective Humoral Immunity in the Central Nervous System Requires Peripheral CD19-Dependent Germinal Center Formation following Coronavirus Encephalomyelitis.
Efficacy and immunogenicity of recombinant swinepox virus expressing the truncated S protein of a novel isolate of porcine epidemic diarrhea virus.
Protection against infectious bronchitis virus by spike ectodomain subunit vaccine.
Development and application of real-time RT-PCR and S1 protein-based indirect ELISA for porcine deltacoronavirus.
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.
Genetic characteristics, pathogenicity, and immunogenicity associated with cell adaptation of a virulent genotype 2b porcine epidemic diarrhea virus.
Evaluation of purified recombinant spike fragments for assessment of the presence of serum neutralizing antibodies against a variant strain of porcine epidemic diarrhea virus.
Chicken mannose binding lectin has antiviral activity towards infectious bronchitis virus.
Variability in biological behaviour, pathogenicity, protectotype and induction of virus neutralizing antibodies by different vaccination programmes to infectious bronchitis virus genotype Q1 strains from Chile.
A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein.
The S2 glycoprotein subunit of porcine epidemic diarrhea virus contains immunodominant neutralizing epitopes.
A spike-specific whole-porcine antibody isolated from a porcine B cell that neutralizes both genogroup 1 and 2 PEDV strains.
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015.
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein.
Evaluation and Comparison of the Pathogenicity and Host Immune Responses Induced by a G2b Taiwan Porcine Epidemic Diarrhea Virus (Strain Pintung 52) and Its Highly Cell-Culture Passaged Strain in Conventional 5-Week-Old Pigs.
Crystal structure of the receptor binding domain of the spike glycoprotein of human betacoronavirus HKU1.
Genetic variability of the S1 subunit of enteric and respiratory bovine coronavirus isolates.
Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.
Neutralization of genotype 2 porcine epidemic diarrhea virus strains by a novel monoclonal antibody.
Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate.
Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains.
Cell Attachment Domains of the Porcine Epidemic Diarrhea Virus Spike Protein Are Key Targets of Neutralizing Antibodies.
Porcine epidemic diarrhea virus virus-like particles produced in insect cells induce specific immune responses in mice.
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
Heat shock protein 70 in lung and kidney of specific-pathogen-free chickens is a receptor-associated protein that interacts with the binding domain of the spike protein of infectious bronchitis virus.
Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.
Identification of a novel recombinant virulent avian infectious bronchitis virus.
Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice.
Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries.
Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding.
MERS-CoV spike protein: a key target for antivirals.
The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
A mouse model for MERS coronavirus-induced acute respiratory distress syndrome.
Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model.
Identification of an infectious bronchitis coronavirus strain exhibiting a classical genotype but altered antigenicity, pathogenicity, and innate immunity profile.
Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.
Rapid detection of viral antibodies based on multifunctional Staphylococcus aureus nanobioprobes.
Characterization of canine coronavirus spread among domestic dogs in Vietnam.
Insights from molecular structure predictions of the infectious bronchitis virus S1 spike glycoprotein.
Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.
Efficient priming of CD4‚ÄâT cells by Langerin-expressing dendritic cells targeted with porcine epidemic diarrhea virus spike protein domains in pigs.
One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.
Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Middle East Respiratory Coronavirus Accessory Protein 4a Inhibits PKR-Mediated Antiviral Stress Responses.
Characterization of a Novel Chimeric Swine Enteric Coronavirus from Diseased Pigs in Central Eastern Europe in 2016.
A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
Infectious bronchitis virus poly-epitope-based vaccine protects chickens from acute infection.
Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates.
Polymorphisms in the S1 spike glycoprotein of Arkansas-type infectious bronchitis virus (IBV) show differential binding to host tissues and altered antigenicity.
Experimental infection of gnotobiotic pigs with the cell-culture-adapted porcine deltacoronavirus strain OH-FD22.
Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy.
Immunogenicity of a recombinant parapoxvirus expressing the spike protein of Porcine epidemic diarrhea virus.
Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens.
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus.
Production and characterization of egg yolk antibody (IgY) against recombinant VP8-S2 antigen.
MERS-CoV spike protein: Targets for vaccines and therapeutics.
Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.
Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection.
Bioinformatics-based Design of Peptide Vaccine Candidates Targeting Spike Protein of MERS-CoV and Immunity analysis in Mice.
Phylogenetic and antigenic characterization of newly isolated porcine epidemic diarrhea viruses in Japan.
Characterization of anti-porcine epidemic diarrhea virus neutralizing activity in mammary secretions.
Development of an equine coronavirus-specific enzyme-linked immunosorbent assay to determine serologic responses in naturally infected horses.
Isolation and Characterization of Dromedary Camel Coronavirus UAE-HKU23 from Dromedaries of the Middle East: Minimal Serological Cross-Reactivity between MERS Coronavirus and Dromedary Camel Coronavirus UAE-HKU23.
Trigger factor assisted soluble expression of recombinant spike protein of porcine epidemic diarrhea virus in Escherichia coli.
Design and Construction of Chimeric VP8-S2 Antigen for Bovine Rotavirus and Bovine Coronavirus.
Epidemic strain YC2014 of porcine epidemic diarrhea virus could provide piglets against homologous challenge.
Reverse Transcription Cross-Priming Amplification-Nucleic Acid Test Strip for Rapid Detection of Porcine Epidemic Diarrhea Virus.
MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques.
S1 domain of the porcine epidemic diarrhea virus spike protein as a vaccine antigen.
Two-way antigenic cross-reactivity between porcine epidemic diarrhea virus and porcine deltacoronavirus.
Immune responses induced by recombinant Bacillus subtilis expressing the spike protein of transmissible gastroenteritis virus in pigs.
Vaccines for the prevention against the threat of MERS-CoV.
Construction of a bivalent DNA vaccine co-expressing S genes of transmissible gastroenteritis virus and porcine epidemic diarrhea virus delivered by attenuated Salmonella typhimurium.
SARS-like WIV1-CoV poised for human emergence.
Spread of Mutant Middle East Respiratory Syndrome Coronavirus with Reduced Affinity to Human CD26 during the South Korean Outbreak.
Responses of the Toll-like receptor and melanoma differentiation-associated protein 5 signaling pathways to avian infectious bronchitis virus infection in chicks.
Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo.
Hepatitis C Virus Resistance to Carbohydrate-Binding Agents.
Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer.
RNA sequencing-based analysis of the spleen transcriptome following infectious bronchitis virus infection of chickens selected for different mannose-binding lectin serum concentrations.
Surface vimentin is critical for the cell entry of SARS-CoV.
Pseudotyping Viral Vectors With Emerging Virus Envelope Proteins.
Development of a Neutralizing Monoclonal Antibody Against Porcine Epidemic Diarrhea Virus S1 Protein.
Activation of RNase L by Murine Coronavirus in Myeloid Cells Is Dependent on Basal Oas Gene Expression and Independent of Virus-Induced Interferon.
An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.
Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases.
Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge.
MERS Vaccine Candidate Offers Promise, but Questions Remain.
Immunogenicity and antigenic relationships among spike proteins of porcine epidemic diarrhea virus subtypes G1 and G2.
An optimised method for the production of MERS-CoV spike expressing viral pseudotypes.
A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence.
Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection.
Reconstitution of the receptor-binding motif of the SARS coronavirus.
Assembly and immunogenicity of baculovirus-derived infectious bronchitis virus-like particles carrying membrane, envelope and the recombinant spike proteins.
Prevalence of canine coronavirus (CCoV) in dog in Japan: detection of CCoV RNA and retrospective serological analysis.
Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease.
A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.
Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody.
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses.
Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.
Two novel neutralizing antigenic epitopes of the s1 subunit protein of a QX-like avian infectious bronchitis virus strain Sczy3 as revealed using a phage display peptide library.
Development of an indirect ELISA based on a truncated S protein of the porcine epidemic diarrhea virus.
Construction of an oral vaccine for transmissible gastroenteritis virus based on the TGEV N gene expressed in an attenuated Salmonella typhimurium vector.
Putative phage-display epitopes of the porcine epidemic diarrhea virus S1 protein and their anti-viral activity.
A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.
Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27.
Anti-infective immunoadhesins from plants.
Evaluation of candidate vaccine approaches for MERS-CoV.
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.
Isolation and characterization of a Korean porcine epidemic diarrhea virus strain KNU-141112.
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.
Decreased neutralizing antigenicity in IBV S1 protein expressed from mammalian cells.
Immunoprophylactic effect of chicken egg yolk antibody (IgY) against a recombinant S1 domain of the porcine epidemic diarrhea virus spike protein in piglets.
Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.
Neutralization Analysis of a Chicken Single-Chain Variable Fragment Derived from an Immune Antibody Library Against Infectious Bronchitis Virus.
Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1.
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
Phage display for identifying peptides that bind the spike protein of transmissible gastroenteritis virus and possess diagnostic potential.
Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
Development of a multi-epitope antigen of S protein-based ELISA for antibodies detection against infectious bronchitis virus.
A novel dromedary camel enterovirus in the family Picornaviridae from dromedaries in the Middle East.
Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins.
Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.
Development and characterization of neutralizing monoclonal antibodies against the S1 subunit protein of QX-like avian infectious bronchitis virus strain Sczy3.
Aptamers in diagnostics and treatment of viral infections.
Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
Antigenic relationships among porcine epidemic diarrhea virus and transmissible gastroenteritis virus strains.
Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A.
Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
Sparse evidence of MERS-CoV infection among animal workers living in Southern Saudi Arabia during 2012.
Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections.
A structural view of coronavirus-receptor interactions.
Comparison of serum neutralization and enzyme-linked immunosorbent assay on sera from porcine epidemic diarrhea virus vaccinated pigs.
Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.
Evaluation of antibody response of killed and live vaccines against porcine epidemic diarrhea virus in a field study.
The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.
Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.
Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM Repertoires.
High-efficiency expression of a receptor-binding domain of SARS-CoV spike protein in tobacco chloroplasts.
Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.
Emergence of pathogenic coronaviruses in cats by homologous recombination between feline and canine coronaviruses.
Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.
Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody.
Immunogenicity and protective efficacy of recombinant S1 domain of the porcine epidemic diarrhea virus spike protein.
Up-regulation of MDP and tuftsin gene expression in Th1 and Th17 cells as an adjuvant for an oral Lactobacillus casei vaccine against anti-transmissible gastroenteritis virus.
Genotypes and serotypes of avian infectious bronchitis viruses isolated during 2009-2011 in Guangxi, China.
Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus.
Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.
Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.
Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein.
Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.
Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.
A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.
Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013.
Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.
Comparative in vivo analysis of recombinant type II feline coronaviruses with truncated and completed ORF3 region.
Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.
Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in spike 1 domain and membrane protein of feline infectious peritonitis virus.
Myosins 1 and 6, myosin light chain kinase, actin and microtubules cooperate during antibody-mediated internalisation and trafficking of membrane-expressed viral antigens in feline infectious peritonitis virus infected monocytes.
Middle East respiratory syndrome coronavirus (MERS-CoV): evidence and speculations.
Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005.
Isolation, propagation, genome analysis and epidemiology of HKU1 betacoronaviruses.
Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus.
Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.
Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation.
A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines.
Adjuvant effects of mannose-binding lectin ligands on the immune response to infectious bronchitis vaccine in chickens with high or low serum mannose-binding lectin concentrations.
Lack of MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi Arabia.
Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.
Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation.
Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013.
Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.
Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.
A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
Receptor-binding domain as a target for developing SARS vaccines.
Manipulation of the porcine epidemic diarrhea virus genome using targeted RNA recombination.
Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.
Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.
Rapid Generation of Human-Like Neutralizing Monoclonal Antibodies in Urgent Preparedness for Influenza Pandemics and Virulent Infectious Diseases.
The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies.
Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC.
Specific serology for emerging human coronaviruses by protein microarray.
Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests.
Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
Identification of immunogenic determinants of the spike protein of SARS-like coronavirus.
Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.
TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine.
Evaluation on the efficacy and immunogenicity of recombinant DNA plasmids expressing spike genes from porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus.
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies.
A DNA prime-protein boost vaccination strategy targeting turkey coronavirus spike protein fragment containing neutralizing epitope against infectious challenge.
Evaluation of antigenic relationship of Guangxi isolates of infectious bronchitis virus.
Astrocyte-derived CXCL10 drives accumulation of antibody-secreting cells in the central nervous system during viral encephalomyelitis.
The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus.
Antigenic variation among recent Japanese isolates of bovine coronaviruses belonging to phylogenetically distinct genetic groups.
Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections.
Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.
Construction of recombinant lactobacilli expressing the core neutralizing epitope (COE) of porcine epidemic diarrhea virus and a fusion protein consisting of COE and  Escherichia coli  heat-labile enterotoxin B, and comparison of the immune responses by orogastric immunization.
The heptide repeat 2 and upstream region of TGEV induces potent cross-neutralizing antibodies against group I coronaviruses.
Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.
Understanding the T cell immune response in SARS coronavirus infection.
Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing.
Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies.
Immunogenicity of a neutralizing epitope from porcine epidemic diarrhea virus: M cell targeting ligand fusion protein expressed in transgenic rice calli.
Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus.
Differences in neutralizing antigenicity between laboratory and clinical isolates of HCoV-229E isolated in Japan in 2004-2008 depend on the S1 region sequence of the spike protein.
Immune responses induced by DNA vaccines bearing Spike gene of PEDV combined with porcine IL-18.
Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.
The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates.
Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria.
Comparative evaluation of two hemagglutinating encephalomyelitis coronavirus vaccine candidates in mice.
Isolation and characterization of a novel Betacoronavirus subgroup A coronavirus, rabbit coronavirus HKU14, from domestic rabbits.
Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.
SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.
Wild animal surveillance for coronavirus HKU1 and potential variants of other coronaviruses.
Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens.
Serotype and genotype diversity of infectious bronchitis viruses isolated during 1985-2008 in Guangxi, China.
Construction and characterization of single-chain variable fragment antibody library derived from germline rearranged immunoglobulin variable genes.
Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection.
Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.
Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcŒ≥R pathway.
Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
Bacterial expression of antigenic sites A and D in the spike protein of transmissible gastroenteritis virus and evaluation of their inhibitory effects on viral infection.
Identification and characterization of a neutralizing-epitope-containing spike protein fragment in turkey coronavirus.
Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.
Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection.
LocaPep: localization of epitopes on protein surfaces using peptides from phage display libraries.
Construction and characterization of Lactobacillus pentosus expressing the D antigenic site of the spike protein of Transmissible gastroenteritis virus.
Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients.
Development of monoclonal antibodies (MAbs) to feline interferon (fIFN)-Œ≥ as tools to evaluate cellular immune responses to feline infectious peritonitis virus (FIPV).
Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response.
Cross-crystal averaging with search models to improve molecular replacement phases.
Antigenic modules in the N-terminal S1 region of the transmissible gastroenteritis virus spike protein.
Characterization and utility of monoclonal antibodies against spike protein of transmissible gastroenteritis virus.
Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus.
Mutation of neutralizing/antibody-dependent enhancing epitope on spike protein and 7b gene of feline infectious peritonitis virus: influences of viral replication in monocytes/macrophages and virulence in cats.
Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses.
Expression of a cholera toxin B subunit-neutralizing epitope of the porcine epidemic diarrhea virus fusion gene in transgenic lettuce (Lactuca sativa L.).
Preparation and characterization of polyclonal antibody against severe acute respiratory syndrome-associated coronavirus spike protein.
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.
Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.
Development, characterization, and application of monoclonal antibodies against severe acute respiratory syndrome coronavirus nucleocapsid protein.
Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.
Identification of NCAM that interacts with the PHE-CoV spike protein.
Binding characterization of determinants in porcine aminopeptidase N, the cellular receptor for transmissible gastroenteritis virus.
Vectored vaccines to protect against PRRSV.
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
A novel B-cell epitope of avian infectious bronchitis virus N protein.
The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice.
Priming with a DNA vaccine and boosting with an inactivated vaccine enhance the immune response against infectious bronchitis virus.
Structural considerations in the fitness landscape of a virus.
Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies.
Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus.
Automated detection of conformational epitopes using phage display Peptide sequences.
Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.
Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening.
Specific real-time reverse transcription-polymerase chain reaction for detection and quantitation of turkey coronavirus RNA in tissues and feces from turkeys infected with turkey coronavirus.
Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134.
Strategies for targeting tetraspanin proteins: potential therapeutic applications in microbial infections.
A protective role for ELR+ chemokines during acute viral encephalomyelitis.
Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein.
Fine specificity of autoantibodies induced by mouse hepatitis virus A59.
Induction of immune response after oral inoculation of mice with Lactobacillus casei surface-displayed porcine epidemic diarrhea viral N protein.
An oral mucosal DNA vaccine for SARS coronavirus infections.
Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
Porcine aminopeptidase N is a functional receptor for the PEDV coronavirus.
Oral immunization of mice with recombinant Lactococcus lactis  expressing porcine transmissible gastroenteritis virus spike  glycoprotein.
CXCL10 and trafficking of virus-specific T cells during coronavirus-induced demyelination.
Immunogenicity difference between the SARS coronavirus and the bat SARS-like coronavirus spike (S) proteins.
A self-assembled fusion protein-based surface plasmon resonance biosensor for rapid diagnosis of severe acute respiratory syndrome.
Recombinant S-layer proteins of Lactobacillus brevis mediating antibody adhesion to calf intestine alleviated neonatal diarrhea syndrome.
Characterization of cytotoxic T-lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine expressing the RGD-integrin-binding motif.
Escherichia coli expressing single-chain Fv on the cell surface as a potential prophylactic of porcine epidemic diarrhea virus.
Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells.
mRNA display design of fibronectin-based intrabodies that detect and inhibit severe acute respiratory syndrome coronavirus nucleocapsid protein.
Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus.
Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain.
Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
Antibody fragment expression and purification.
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.
SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice.
Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.
SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro.
A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.
Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine.
Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection.
Analysis of severe acute respiratory syndrome coronavirus structural proteins in virus-like particle assembly.
Studies of SARS virus vaccines.
Mechanisms of lymphocyte loss in SARS coronavirus infection.
Establishment and characterization of monoclonal antibodies against SARS coronavirus.
Identification of sugar residues involved in the binding of TGEV to porcine brush border membranes.
Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins.
The expression and antigenicity of a truncated spike-nucleocapsid fusion protein of severe acute respiratory syndrome-associated coronavirus.
Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice.
Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway.
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection.
Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody.
Surface-expressed viral proteins in feline infectious peritonitis virus-infected monocytes are internalized through a clathrin- and caveolae-independent pathway.
T cell responses to whole SARS coronavirus in humans.
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.
Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles.
Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
Development of human single-chain antibodies against SARS-associated coronavirus.
A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV.
DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans.
Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus.
Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2.
Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.
Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.
A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters.
Identification of two novel B cell epitopes on porcine epidemic diarrhea virus spike protein.
SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
Characterization and epitope mapping of monoclonal antibodies to the nucleocapsid protein of severe acute respiratory syndrome coronavirus.
Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species.
Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.
Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium.
Evidence for differential roles for NKG2D receptor signaling in innate host defense against coronavirus-induced neurological and liver disease.
Development and application of a safe SARS-CoV neutralization assay based on lentiviral vectors pseudotyped with SARS-CoV spike protein.
Spike protein region (aa 636789) of porcine epidemic diarrhea virus is essential for induction of neutralizing antibodies.
The GPRLQPY motif located at the carboxy-terminal of the spike protein induces antibodies that neutralize Porcine epidemic diarrhea virus.
Novel small-molecule inhibitors of transmissible gastroenteritis virus.
Severe outbreak of bovine coronavirus infection in dairy cattle during the warmer season.
Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.
Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.
First isolation of cytopathogenic bovine torovirus in cell culture from a calf with diarrhea.
Construction of recombinant Lactococcus lactis expressing porcine transmissible gastroenteritis spike glycoprotein and analysis of immunogenicity.
Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice.
Identification of synthetic vaccine candidates against SARS CoV infection.
Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV.
Comparison of immunoglobulin G responses to the spike and nucleocapsid proteins of severe acute respiratory syndrome (SARS) coronavirus in patients with SARS.
Porcine aminopeptidase N is a functional receptor for the PEDV coronavirus.
Sequence analysis of the partial spike glycoprotein gene of porcine epidemic diarrhea viruses isolated in Korea.
The infectivity and pathogenicity of a group 2 bovine coronavirus in pups.
Identification and characterization of dominant helper T-cell epitopes in the nucleocapsid protein of severe acute respiratory syndrome coronavirus.
Computational characterization and design of SARS coronavirus receptor recognition and antibody neutralization.
A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage.
Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
Production and characterization of monoclonal antibodies to (poly100)S1 protein of avian infectious bronchitis virus.
Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS.
An antibody derivative expressed from viral vectors passively immunizes pigs against transmissible gastroenteritis virus infection when supplied orally in crude plant extracts.
Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models.
Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies.
The Immunobiology of SARS*.
Serological and molecular evidence that canine respiratory coronavirus is circulating in Italy.
Baculovirus surface display of SARS coronavirus (SARS-CoV) spike protein and immunogenicity of the displayed protein in mice models.
Recombinant dimeric small immunoproteins neutralize transmissible gastroenteritis virus infectivity efficiently in vitro and confer passive immunity in vivo.
Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse.
Infectious bronchitis virus serotypes in poultry flocks in Jordan.
Murine coronavirus-induced oligodendrocyte apoptosis is mediated through the activation of the Fas signaling pathway.
Mutational analysis of aminopeptidase N, a receptor for several group 1 coronaviruses, identifies key determinants of viral host range.
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV.
A study on antigenicity and receptor-binding ability of fragment 450-650 of the spike protein of SARS coronavirus.
Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro.
Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus.
Antibody-mediated targeting of viral vectors to the Fc receptor expressed on acute myeloid leukemia cells.
Protein nanopatterns and biosensors using gold binding polypeptide as a fusion partner.
Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models.
Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.
Identification of mimotope peptides which bind to the SARS-CoV spike protein specific monoclonal antibody 2C5 with phage-displayed peptides library.
Complete genomic sequences, a key residue in the spike protein and deletions in nonstructural protein 3b of US strains of the virulent and attenuated coronaviruses, transmissible gastroenteritis virus and porcine respiratory coronavirus.
SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus.
Use of virus vectors for the expression in plants of active full-length and single chain anti-coronavirus antibodies.
Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: implications for the functional roles of S2 subunit.
Coronavirus nucleocapsid protein is an RNA chaperone.
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R.
Phage-displayed peptides having antigenic similarities with porcine epidemic diarrhea virus (PEDV) neutralizing epitopes.
Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 August 2005, London, UK.
Antigenic and cellular localisation analysis of the severe acute respiratory syndrome coronavirus nucleocapsid protein using monoclonal antibodies.
Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine.
Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines.
Amino acids 15-28 in the ectodomain of SARS coronavirus 3a protein induces neutralizing antibodies.
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
Inhibition of human coronavirus NL63 infection at early stages of the replication cycle.
Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients.
Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus.
Transmissible gastroenteritis virus infection: a vanishing specter.
Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus.
Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs.
Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides.
A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity.
Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody.
Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice.
High expression level of soluble SARS spike protein mediated by adenovirus in HEK293 cells.
SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.
A human neutralizing antibody against a conformational epitope shared by oligomeric SARS S1 protein.
Biological properties of the chick infectious bronchitis virus isolated in Russia.
A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice.
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
The prevalence of a group 2 coronavirus in dogs in Japan.
Functional peptide microarrays for specific and sensitive antibody diagnostics.
CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS.
Receptor-binding ability of fragments 260-600 and 397-796 of SARS-associated coronavirus spike protein.
SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens.
Polyhydroxyalkanoate chip for the specific immobilization of recombinant proteins and its applications in immunodiagnostics.
Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus.
7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase.
Solution structure of the X4 protein coded by the SARS related coronavirus reveals an immunoglobulin like fold and suggests a binding activity to integrin I domains.
Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.
Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals.
Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization.
Cloning of ACE-2 gene encoding the functional receptor for the SARS coronavirus and its expression in eukaryotic cells.
Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.
Preparation and identification of monoclonal antibodies against SARS-CoV putative protein X4.
SARS Immunity and Vaccination.
A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach.
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats.
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor.
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV).
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus.
Identification and antigenic epitope mapping of immunodominant region amino residues 510 to 672 on the spike protein of the severe acute respiratory syndrome coronavirus.
Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity.
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
Vaccine design for severe acute respiratory syndrome coronavirus.
Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein.
Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats.
SARS vaccine development.
SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
Pathogenesis of severe acute respiratory syndrome.
An immunofluorescence assay for the detection of SARS associated coronavirus antibody based on recombinant nucleocapsid antigen and its application.
A human SARS-CoV neutralizing antibody against epitope on S2 protein.
Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).
Production of a monoclonal antibody against SARS-CoV spike protein with single intrasplenic immunization of plasmid DNA.
Characterization of monoclonal antibody against SARS coronavirus nucleocapsid antigen and development of an antigen capture ELISA.
Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
Mutational and inhibitive analysis of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer-based assays.
Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies.
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS.
Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody.
Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection.
Molecular advances in the cell biology of SARS-CoV and current disease prevention strategies.
A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential.
Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein.
Biochemical and immunological studies of nucleocapsid proteins of severe acute respiratory syndrome and 229E human coronaviruses.
Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.
The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice.
Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
Current status of anti-SARS agents.
Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library.
B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.
Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.
Cloning of the Atlantic salmon (Salmo salar) IL-1 receptor associated protein.
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production.
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.
Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.
Structure and intracellular targeting of the SARS-coronavirus Orf7a accessory protein.
Potent neutralization antibody elicited in mice by SARS-associated coronavirus spike protein S1 domain.
Construction and screening of human phage antibody library against SARS virus.
The epitope study on the SARS-CoV nucleocapsid protein.
A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor.
Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.
Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets.
Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus.
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine.
The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells.
Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine.
A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection.
Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.
Ceacam1a-/- mice are completely resistant to infection by murine coronavirus mouse hepatitis virus A59.
Sequence similarity and structural homologies are involved in the autoimmune response elicited by mouse hepatitis virus A59.
Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.
A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.
Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein.
A novel sorting signal for intracellular localization is present in the S protein of a porcine coronavirus but absent from severe acute respiratory syndrome-associated coronavirus.
Recombinant scFv antibodies against E protein and N protein of severe acute respiratory syndrome virus.
Coronavirus infection of spotted hyenas in the Serengeti ecosystem.
Human coronavirus 229E binds to CD13 in rafts and enters the cell through caveolae.
The 3D structure analysis of SARS-CoV S1 protein reveals a link to influenza virus neuraminidase and implications for drug and antibody discovery.
Disease-specific B Cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens.
Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein.
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus.
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
Generation of the transgenic potato expressing full-length spike protein of infectious bronchitis virus.
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
SARS corona virus peptides recognized by antibodies in the sera of convalescent cases.
Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein.
An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
Identification of two antigenic epitopes on SARS-CoV spike protein.
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients.
Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV.
T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS.
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.
Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis.
Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: perspective for SARS vaccine development.
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.
Preparation and characterization of monoclonal antibodies against S1 domain at N-terminal residues 249 to 667 of SARS-associated coronavirus S1 protein.
Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein.
Mitochondrial HSP70, HSP40, and HSP60 bind to the 3' untranslated region of the Murine hepatitis virus genome.
Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
Expression, purification and identification of recombinant SARS coronavirus membrane protein.
N-terminal domain of the murine coronavirus receptor CEACAM1 is responsible for fusogenic activation and conformational changes of the spike protein.
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.
Effects of a SARS-associated coronavirus vaccine in monkeys.
The SARS-CoV S glycoprotein: expression and functional characterization.
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
Neutralization of enteric coronaviruses with Escherichia coli cells expressing single-chain Fv-autotransporter fusions.
Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP.
Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus.
Transgenic potato containing immunogenic gene of avian coronavirus and its immunogenicity in mice.
Antibody-mediated protection against cytotoxic T-cell escape in coronavirus-induced demyelination.
Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein.
Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China.
Expression and purification of recombinant SARS coronavirus spike protein.
The study of cis-element HNF4 in the regulation of mfg12 prothrombinase/fibroleukin gene expression in response to nucleocapsid protein of MHV-3.
Protection of chickens from infectious bronchitis by in ovo and intramuscular vaccination with a DNA vaccine expressing the S1 glycoprotein.
Identification of an epitope of SARS-coronavirus nucleocapsid protein.
Partial sequence of the spike glycoprotein gene of transmissible gastroenteritis viruses isolated in Korea.
The Genome sequence of the SARS-associated coronavirus.
Control of central nervous system viral persistence by neutralizing antibody.
Serum levels of mannan-binding lectin in chickens prior to and during experimental infection with avian infectious bronchitis virus.
Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E.
STAT1 and STAT3 alpha/beta splice form activation predicts host responses in mouse hepatitis virus type 3 infection.
Construction and immunogenicity studies of recombinant fowl poxvirus containing the S1 gene of Massachusetts 41 strain of infectious bronchitis virus.
Identification of the epitope region capable of inducing neutralizing antibodies against the porcine epidemic diarrhea virus.
Receptor-induced conformational changes of murine coronavirus spike protein.
Genetic and antigenic diversity in avian infectious bronchitis virus isolates of the 1940s.
The spike but not the hemagglutinin/esterase protein of bovine coronavirus is necessary and sufficient for viral infection.
An ELISA for antibodies against infectious bronchitis virus using an S1 spike polypeptide.
Cross-protection studies between respiratory and calf diarrhea and winter dysentery coronavirus strains in calves and RT-PCR and nested PCR for their detection.
Antigenic and genomic relatedness of turkey-origin coronaviruses, bovine coronaviruses, and infectious bronchitis virus of chickens.
Involvement in fusion activity of an epitope in the S2 subunit of murine coronavirus spike protein.
Soluble receptor potentiates receptor-independent infection by murine coronavirus.
Organization of two transmissible gastroenteritis coronavirus membrane protein topologies within the virion and core.
Neutralisation and binding of VHS virus by monovalent antibody fragments.
DNA mediated immunization with encoding the nucleoprotein gene of porcine transmissible gastroenteritis virus.
Targeted disruption of the Ceacam1 (MHVR) gene leads to reduced susceptibility of mice to mouse hepatitis virus infection.
B-cell-mediated lysis of cells infected with the neurotropic JHM strain of mouse hepatitis virus.
Spike glycoprotein cleavage recognition site analysis of infectious bronchitis virus.
Mouse hepatitis virus replicase protein complexes are translocated to sites of M protein accumulation in the ERGIC at late times of infection.
Enhanced immune responses to viral epitopes by combining macrophage-inducible expression with multimeric display on a Salmonella vector.
Mitochondrial aconitase binds to the 3' untranslated region of the mouse hepatitis virus genome.
A single amino acid change within antigenic domain II of the spike protein of bovine coronavirus confers resistance to virus neutralization.
Efficacy of a transmissible gastroenteritis coronavirus with an altered ORF-3 gene.
Antibody responses to respiratory coronavirus infections of cattle during shipping fever pathogenesis.
Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles.
Relationship between serotypes and genotypes based on the hypervariable region of the S1 gene of infectious bronchitis virus.
The membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability.
Construction and characterization of recombinant porcine adenovirus serotype 5 expressing the transmissible gastroenteritis virus spike gene.
Characterization of a coronavirus isolated from a diarrheic foal.
Functional analysis of an epitope in the S2 subunit of the murine coronavirus spike protein: involvement in fusion activity.
RNase L-independent specific 28S rRNA cleavage in murine coronavirus-infected cells.
Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides.
Immunogenicity of porcine transmissible gastroenteritis virus spike protein expressed in plants.
Neutralization of feline infectious peritonitis virus: preparation of monoclonal antibody that shows cell tropism in neutralizing activity after viral absorption into the cells.
Antigenic variation among bovine enteric coronaviruses (BECV) and bovine respiratory coronaviruses (BRCV) detected using monoclonal antibodies.
Interference with virus and bacteria replication by the tissue specific expression of antibodies and interfering molecules.
Characterization of the sialic acid binding activity of transmissible gastroenteritis coronavirus by analysis of haemagglutination-deficient mutants.
Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier.
The nucleocapsid protein of coronavirus mouse hepatitis virus interacts with the cellular heterogeneous nuclear ribonucleoprotein A1 in vitro and in vivo.
Infectious bronchitis virus S2 gene sequence variability may affect S1 subunit specific antibody binding.
Mouse hepatitis virus strain JHM infects a human hepatocellular carcinoma cell line.
Difference in Bgp-independent fusion activity among mouse hepatitis viruses.
Active immunity and T-cell populations in pigs intraperitoneally inoculated with baculovirus-expressed transmissible gastroenteritis virus structural proteins.
Selection of antigenic variants of the S glycoprotein of feline infectious peritonitis virus and analysis of antigenic sites involved in neutralization.
Detection of bovine coronaviruses from adult cows with epizootic diarrhea and their antigenic and biological diversities.
Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences.
Antibody prevents virus reactivation within the central nervous system.
Evaluation of the baculovirus-expressed S glycoprotein of transmissible gastroenteritis virus (TGEV) as antigen in a competition ELISA to differentiate porcine respiratory coronavirus from TGEV antibodies in pigs.
Characterization of the expression and immunogenicity of the ns4b protein of human coronavirus 229E.
Characterization of haemagglutinin-esterase protein (HE) of murine corona virus DVIM by monoclonal antibodies.
Persistent infection promotes cross-species transmissibility of mouse hepatitis virus.
Antibody and cytokine responses in kittens during the development of feline infectious peritonitis (FIP).
Expression of immunogenic glycoprotein S polypeptides from transmissible gastroenteritis coronavirus in transgenic plants.
Lactogenic immunity in transgenic mice producing recombinant antibodies neutralizing coronavirus.
Interference of coronavirus infection by expression of IgG or IgA virus neutralizing antibodies.
A monoclonal antibody blocking ELISA for the detection of IBV antibodies in fowl.
Cytotoxic T lymphocyte responses to infectious bronchitis virus infection.
Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection.
Proteolytic processing of the polyprotein encoded by ORF1b of the coronavirus infectious bronchitis virus (IBV).
Processing of the MHV-A59 gene 1 polyprotein by the 3C-like proteinase.
Human biliary glycoproteins function as receptors for interspecies transfer of mouse hepatitis virus.
Neutralization of MHV-A59 by soluble recombinant receptor glycoproteins.
Purified, soluble recombinant mouse hepatitis virus receptor, Bgp1(b), and Bgp2 murine coronavirus receptors differ in mouse hepatitis virus binding and neutralizing activities.
Differences in virus receptor for type I and type II feline infectious peritonitis virus.
Screening of a small set of random peptides: a new strategy to identify synthetic peptides that mimic epitopes.
Mice lacking IL-12 develop polarized Th1 cells during viral infection.
Transgenic mice secreting coronavirus neutralizing antibodies into the milk.
Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk.
Development and evaluation of an ELISA to measure antibody responses to both the nucleocapsid and spike proteins of canine coronavirus.
Mutational analysis of the virus and monoclonal antibody binding sites in MHVR, the cellular receptor of the murine coronavirus mouse hepatitis virus strain A59.
A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice.
Mouse hepatitis virus infection induces an early, transient calcium influx in mouse astrocytoma cells.
The murine coronavirus mouse hepatitis virus strain A59 from persistently infected murine cells exhibits an extended host range.
The function of the spike protein of mouse hepatitis virus strain A59 can be studied on virus-like particles: cleavage is not required for infectivity.
Expression of interferon-gamma by a coronavirus defective-interfering RNA vector and its effect on viral replication, spread, and pathogenicity.
Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies.
No evidence for quasispecies populations during persistence of the coronavirus mouse hepatitis virus JHM: sequence conservation within the surface glycoprotein gene S in Lewis rats.
A role for naturally occurring variation of the murine coronavirus spike protein in stabilizing association with the cellular receptor.
Identification of a contiguous 6-residue determinant in the MHV receptor that controls the level of virion binding to cells.
Active and passive immune responses to transmissible gastroenteritis virus (TGEV) in swine inoculated with recombinant baculovirus-expressed TGEV spike glycoprotein vaccines.
An Escherichia coli CS31A fibrillum chimera capable of inducing memory antibodies in outbred mice following booster immunization with the entero-pathogenic coronavirus transmissible gastroenteritis virus.
Human carcinoembryonic antigen and biliary glycoprotein can serve as mouse hepatitis virus receptors.
Two amino acid changes at the N-terminus of transmissible gastroenteritis coronavirus spike protein result in the loss of enteric tropism.
Identification of amino acids involved in a serotype and neutralization specific epitope within the s1 subunit of avian infectious bronchitis virus.
Characterization of phage-displayed recombinant anti-idiotypic antibody fragments against coronavirus-neutralizing monoclonal antibodies.
Reconstituted coronavirus TGEV virosomes lose the virus ability to induce porcine interferon-alpha production.
Reconstituted coronavirus TGEV virosomes lose the virus ability to induce porcine interferon-alpha production.
Mouse hepatitis virus is cleared from the central nervous systems of mice lacking perforin-mediated cytolysis.
Characterization of monoclonal antibodies to the hemagglutinin-esterase glycoprotein of a bovine coronavirus associated with winter dysentery and cross-reactivity to field isolates.
Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies.
Genetic control of anti-idiotypic vaccination against coronavirus infection.
The major subunit ClpG of Escherichia coli CS31A fibrillae as an expression vector for different combinations of two TGEV coronavirus epitopes.
Analysis of the serotype-specific epitopes of avian infectious bronchitis virus strains Ark99 and Mass41.
Spike glycoprotein-mediated fusion in biliary glycoprotein-independent cell-associated spread of mouse hepatitis virus infection.
Characterization of a 105-kDa polypeptide encoded in gene 1 of the human coronavirus HCV 229E.
Transmissible gastroenteritis coronavirus, but not the related porcine respiratory coronavirus, has a sialic acid (N-glycolylneuraminic acid) binding activity.
Difference in virus-binding activity of two distinct receptor proteins for mouse hepatitis virus.
Expression of the recombinant anchorless N-terminal domain of mouse hepatitis virus (MHV) receptor makes hamster of human cells susceptible to MHV infection.
Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection.
Attachment glycoproteins and receptor specificity of rat coronaviruses.
A continuous epitope from transmissible gastroenteritis virus S protein fused to E. coli heat-labile toxin B subunit expressed by attenuated Salmonella induces serum and secretory immunity.
An adenovirus recombinant expressing the spike glycoprotein of porcine respiratory coronavirus is immunogenic in swine.
Isolation of coronaviruses antigenically indistinguishable from bovine coronavirus from wild ruminants with diarrhea.
Experimental evidence of recombination in coronavirus infectious bronchitis virus.
Induction of antibodies protecting against transmissible gastroenteritis coronavirus (TGEV) by recombinant adenovirus expressing TGEV spike protein.
A transmissible gastroenteritis coronavirus nucleoprotein epitope elicits T helper cells that collaborate in the in vitro antibody synthesis to the three major structural viral proteins.
Cellular immune responses of pigs after primary inoculation with porcine respiratory coronavirus or transmissible gastroenteritis virus and challenge with transmissible gastroenteritis virus.
Tumor necrosis factor expression during mouse hepatitis virus-induced demyelinating encephalomyelitis.
Membrane protein molecules of transmissible gastroenteritis coronavirus also expose the carboxy-terminal region on the external surface of the virion.
Site-specific alteration of transmissible gastroenteritis virus spike protein results in markedly reduced pathogenicity.
An extracellular matrix protein of jellyfish homologous to mammalian fibrillins forms different fibrils depending on the life stage of the animal.
Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement.
Protection from lethal coronavirus infection by immunoglobulin fragments.
Localization of neurovirulence determinant for rats on the S1 subunit of murine coronavirus JHMV.
Coronavirus-induced encephalomyelitis: balance between protection and immune pathology depends on the immunization schedule with spike protein S.
Interaction of mouse hepatitis virus (MHV) spike glycoprotein with receptor glycoprotein MHVR is required for infection with an MHV strain that expresses the hemagglutinin-esterase glycoprotein.
Overexpression of TGEV cell receptor impairs the production of virus particles.
Localization of neutralizing epitopes and receptor-binding site in murine coronavirus spike protein.
MHVR-independent cell-cell spread of mouse hepatitis virus infection requires neutral pH fusion.
Multiple receptor-dependent steps determine the species specificity of HCV-229E infection.
Cellular receptors for transmissible gastroenteritis virus on porcine enterocytes.
Functional domains in the spike protein of transmissible gastroenteritis virus.
Biological and molecular differentiation between coronaviruses associated with neonatal calf diarrhoea and winter dysentery in adult cattle.
Expression and immunogenicity of the spike glycoprotein of porcine respiratory coronavirus encoded in the E3 region of adenovirus.
Cloning and expression of FECV spike gene in vaccinia virus. Immunization with FECV S causes early death after FIPV challenge.
Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus.
Production and immunogenicity of multiple antigenic peptide (MAP) constructs derived from the S1 glycoprotein of infectious bronchitis virus (IBV).
Neurovirulence for rats of the JHMV variants escaped from neutralization with the S1-specific monoclonal antibodies.
Induction of a protective immune response to murine coronavirus with non-internal image anti-idiotypic antibodies.
Characterization of human T cell clones specific for coronavirus 229E.
A highly conserved epitope on the spike protein of infectious bronchitis virus.
Anti-idiotypic antibodies: biological function and structural studies.
Structure of an anti-idiotypic Fab against feline peritonitis virus-neutralizing antibody and a comparison with the complexed Fab.
A novel variant of avian infectious bronchitis virus resulting from recombination among three different strains.
Antigenic and biological comparisons of bovine coronaviruses derived from neonatal calf diarrhea and winter dysentery of adult cattle.
The v-sis oncoprotein loses transforming activity when targeted to the early Golgi complex.
Localization of the Lys, Asp, Glu, Leu tetrapeptide receptor to the Golgi complex and the intermediate compartment in mammalian cells.
Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein.
Evidence for a putative second receptor for porcine transmissible gastroenteritis virus on the villous enterocytes of newborn pigs.
Characterization of the IgA and subclass IgG responses to neutralizing epitopes after infection of pregnant sows with the transmissible gastroenteritis virus or the antigenically related porcine respiratory coronavirus.
Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein.
Single amino acid changes in the S2 subunit of the MHV surface glycoprotein confer resistance to neutralization by S1 subunit-specific monoclonal antibody.
Mouse hepatitis virus gene 5b protein is a new virion envelope protein.
Human coronavirus OC43 interacts with major histocompatibility complex class I molecules at the cell surface to establish infection.
Determinants essential for the transmissible gastroenteritis virus-receptor interaction reside within a domain of aminopeptidase-N that is distinct from the enzymatic site.
Location of antibody epitopes within the mouse hepatitis virus nucleocapsid protein.
Distribution and trafficking of JHM coronavirus structural proteins and virions in primary neurons and the OBL-21 neuronal cell line.
Crystal structure of an idiotype-anti-idiotype Fab complex.
The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens.
Immunogenicity of the S protein of transmissible gastroenteritis virus expressed in baculovirus.
The role of IgG subclass of mouse monoclonal antibodies in antibody-dependent enhancement of feline infectious peritonitis virus infection of feline macrophages.
Molecular mimicry between Fc receptors and viral antigens.
Synthetic peptides as receptors in affinity sensors: a feasibility study.
Expression of the S1 and S2 subunits of murine coronavirus JHMV spike protein by a vaccinia virus transient expression system.
Coronavirus immunogens.
Localization of the RNA-binding domain of mouse hepatitis virus nucleocapsid protein.
Inhibition of appearance of pH-dependent virus-cell fusion by neutralizing monoclonal antibodies to transmissible gastroenteritis virus.
Induction of protective immunity against coronavirus-induced encephalomyelitis: evidence for an important role of CD8+ T cells in vivo.
Neutralization and fusion inhibition activities of monoclonal antibodies specific for the S1 subunit of the spike protein of neurovirulent murine coronavirus JHMV c1-2 variant.
HLA class I antigen serves as a receptor for human coronavirus OC43.
Mouse hepatitis virus strain A59 and blocking antireceptor monoclonal antibody bind to the N-terminal domain of cellular receptor.
Identification of an immunodominant linear neutralization domain on the S2 portion of the murine coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure.
Several members of the mouse carcinoembryonic antigen-related glycoprotein family are functional receptors for the coronavirus mouse hepatitis virus-A59.
Characterization of monoclonal antibodies to bovine enteric coronavirus and antigenic variability among Quebec isolates.
Evolution and tropism of transmissible gastroenteritis coronavirus.
Virus-ligand interactions of OC43 coronavirus with cell membranes.
Molecular mimicry between S peplomer proteins of coronaviruses (MHV, BCV, TGEV and IBV) and Fc receptor.
Characterization of a monoclonal antibody resistant variant of MHV.
Enhancement and neutralization of feline infectious peritonitis virus infection in feline macrophages by neutralizing monoclonal antibodies recognizing different epitopes.
Epitopes on the spike protein of a nephropathogenic strain of infectious bronchitis virus.
Bovine coronavirus spike glycoprotein: localization of an immunodominant region at the amino-terminal end of S2.
Coronavirus species specificity: murine coronavirus binds to a mouse-specific epitope on its carcinoembryonic antigen-related receptor glycoprotein.
Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus.
Epitope specificity of protective lactogenic immunity against swine transmissible gastroenteritis virus.
Antigen selection and presentation to protect against transmissible gastroenteritis coronavirus.
Production and characterization of monoclonal antibodies to three infectious bronchitis virus serotypes.
Synthesis and processing of the haemagglutinin-esterase glycoprotein of bovine coronavirus encoded in the E3 region of adenovirus.
Genetic evolution and tropism of transmissible gastroenteritis coronaviruses.
Antigenic variation among transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus strains detected with monoclonal antibodies to the S protein of TGEV.
Bovine coronavirus peplomer glycoproteins: detailed antigenic analyses of S1, S2 and HE.
Binding of the coronavirus mouse hepatitis virus A59 to its receptor expressed from a recombinant vaccinia virus depends on posttranslational processing of the receptor glycoprotein.
Human aminopeptidase N is a receptor for human coronavirus 229E.
Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV.
Antigenic structure of transmissible gastroenteritis virus nucleoprotein.
Molecular cloning and expression of a spike protein of neurovirulent murine coronavirus JHMV variant cl-2.
Coronavirus infection in mink (Mustela vison). Serological evidence of infection with a coronavirus related to transmissible gastroenteritis virus and porcine epidemic diarrhea virus.
Location of antigenic sites defined by neutralizing monoclonal antibodies on the S1 avian infectious bronchitis virus glycopolypeptide.
Sequence analysis of the spike protein gene of murine coronavirus variants: study of genetic sites affecting neuropathogenicity.
Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages.
Single amino acid changes in the viral glycoprotein M affect induction of alpha interferon by the coronavirus transmissible gastroenteritis virus.
MHV S peplomer protein expressed by a recombinant vaccinia virus vector exhibits IgG Fc-receptor activity.
Antiidiotypic vaccination against murine coronavirus infection.
A conserved coronavirus epitope, critical in virus neutralization, mimicked by internal-image monoclonal anti-idiotypic antibodies.
Processing and antigenicity of entire and anchor-free spike glycoprotein S of coronavirus TGEV expressed by recombinant baculovirus.
Nucleocapsid or spike protein-specific CD4+ T lymphocytes protect against coronavirus-induced encephalomyelitis in the absence of CD8+ T cells.
Structural analysis of the conformational domains involved in neutralization of bovine coronavirus using deletion mutants of the spike glycoprotein S1 subunit expressed by recombinant baculoviruses.
Comparison of bovine coronavirus (BCV) antigens: monoclonal antibodies to the spike glycoprotein distinguish between vaccine and wild-type strains.
An ELISA for the detection of serum antibodies to both transmissible gastroenteritis virus and porcine respiratory coronavirus.
Localization of antigenic sites on the surface glycoprotein of mouse hepatitis virus.
Residues involved in the antigenic sites of transmissible gastroenteritis coronavirus S glycoprotein.
Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins.
Intracellular processing of the porcine coronavirus transmissible gastroenteritis virus spike protein expressed by recombinant vaccinia virus.
Immunogenicity of peptides simulating a neutralization epitope of transmissible gastroenteritis virus.
Localization of major neutralizing epitopes on the S1 polypeptide of the murine coronavirus peplomer glycoprotein.
Monoclonal antibody analysis of a unique macrophage procoagulant activity induced by murine hepatitis virus strain 3 infection.
Analysis of murine coronavirus surface glycoprotein functions by using monoclonal antibodies.
Characterization of monoclonal antibodies against feline infectious peritonitis virus type II and antigenic relationship between feline, porcine, and canine coronaviruses.
Differentiation between transmissible gastroenteritis virus and porcine respiratory coronavirus using a cDNA probe.
Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection.
Assembly of coronavirus spike protein into trimers and its role in epitope expression.
Analysis of the S spike (peplomer) glycoprotein of bovine coronavirus synthesized in insect cells.
Serological and molecular characterization of three enteric isolates of infectious bronchitis virus of chickens.
The E1 glycoprotein of an avian coronavirus is targeted to the cis Golgi complex.
Antigenic domains on the peplomer protein of avian infectious bronchitis virus: correlation with biological functions.
Mechanisms of transmissible gastroenteritis coronavirus neutralization.
Purification of the 110-kilodalton glycoprotein receptor for mouse hepatitis virus (MHV)-A59 from mouse liver and identification of a nonfunctional, homologous protein in MHV-resistant SJL/J mice.
Analysis and simulation of a neutralizing epitope of transmissible gastroenteritis virus.
Antigenic and genomic relationships among turkey and bovine enteric coronaviruses.
Four major antigenic sites of the coronavirus transmissible gastroenteritis virus are located on the amino-terminal half of spike glycoprotein S.
Monoclonal antibodies to the peplomer glycoprotein of coronavirus mouse hepatitis virus identify two subunits and detect a conformational change in the subunit released under mild alkaline conditions.
Immunoglobulin Fc binding activity is associated with the mouse hepatitis virus E2 peplomer protein.
Expression and secretion of the bovine coronavirus hemagglutinin-esterase glycoprotein by insect cells infected with recombinant baculoviruses.
Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization.
Localization of antigenic sites of the E2 glycoprotein of transmissible gastroenteritis coronavirus.
Mouse hepatitis virus ORF 2a is expressed in the cytosol of infected mouse fibroblasts.
Antigenic homology among coronaviruses related to transmissible gastroenteritis virus.
Characterization and reactivity of monoclonal antibodies to the Miller strain of transmissible gastroenteritis virus of swine.
Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein.
Protection from lethal coronavirus infection by affinity-purified spike glycoprotein of murine hepatitis virus, strain A59.
MHV-resistant SJL/J mice express a non-functional homolog to the MHV receptor glycoprotein.
Infection with a new porcine respiratory coronavirus in Denmark: serologic differentiation from transmissible gastroenteritis virus using monoclonal antibodies.
Monoclonal antibody-selected variants of MHV-4 contain substitutions and deletions in the E2 spike glycoprotein.
Molecular basis of the variation exhibited by avian infectious bronchitis coronavirus (IBV).
Immunogenicity of recombinant feline infectious peritonitis virus spike protein in mice and kittens.
Expression of the spike protein of murine coronavirus JHM using a baculovirus vector.
Protection of mice from lethal coronavirus MHV-A59 infection by monoclonal affinity-purified spike glycoprotein.
Linear neutralizing epitopes on the peplomer protein of coronaviruses.
Topological and functional analysis of epitopes on the S(E2) and HE(E3) glycoproteins of bovine enteric coronavirus.
Location of antigenic sites of the S-glycoprotein of transmissible gastroenteritis virus and their conservation in coronaviruses.
Enteric coronavirus TGEV: mapping of four major antigenic determinants in the amino half of peplomer protein E 2.
Binding of antibodies that strongly neutralise infectious bronchitis virus is dependent on the glycosylation of the viral peplomer protein.
Expression of the peplomer glycoprotein of murine coronavirus JHM using a baculovirus vector.
Analysis of an immunodominant region of infectious bronchitis virus.
Characterization of infectious bronchitis virus using monoclonal antibodies.
Antigenic and polypeptide structure of turkey enteric coronaviruses as defined by monoclonal antibodies.
Characterization of monoclonal and polyclonal antibodies to bovine enteric coronavirus: establishment of an efficient ELISA for antigen detection in feces.
Monoclonal antibodies to bovine coronavirus glycoproteins E2 and E3: demonstration of in vivo virus-neutralizing activity.
Induction of transmissible gastroenteritis coronavirus-neutralizing antibodies in vitro by virus-specific T helper cell hybridomas.
Mapping of neutralizing epitopes to fragments of the bovine coronavirus E2 protein by proteolysis of antigen-antibody complexes.
Amino acid sequence of a conserved neutralizing epitope of murine coronaviruses.
Serologic response of domestic ferrets (Mustela putorius furo) to canine distemper and rabies virus vaccines.
Induction of neutralizing antibodies to transmissible gastroenteritis virus by anti-idiotypic antibodies.
Epitope mapping and the detection of transmissible gastroenteritis viral proteins in cell culture using biotinylated monoclonal antibodies in a fixed-cell ELISA.
Antigenicity of the peplomer protein of infectious bronchitis virus.
Characterization of group II avian adenoviruses with a panel of monoclonal antibodies.
Amino acids within hypervariable region 1 of avian coronavirus IBV (Massachusetts serotype) spike glycoprotein are associated with neutralization epitopes.
Vaccination against lethal coronavirus-induced encephalitis with a synthetic decapeptide homologous to a domain in the predicted peplomer stalk.
Antigenic differentiation between transmissible gastroenteritis virus of swine and a related porcine respiratory coronavirus.
Transmissible gastroenteritis.
Antigenic structure of the E2 glycoprotein from transmissible gastroenteritis coronavirus.
Differentiation of porcine coronavirus from transmissible gastroenteritis virus.
Induction of alpha interferon by transmissible gastroenteritis coronavirus: role of transmembrane glycoprotein E1.
The peplomer protein E2 of coronavirus JHM as a determinant of neurovirulence: definition of critical epitopes by variant analysis.
Epitopes on the peplomer protein of infectious bronchitis virus strain M41 as defined by monoclonal antibodies.
Monoclonal antibodies to bovine coronavirus: characteristics and topographical mapping of neutralizing epitopes on the E2 and E3 glycoproteins.
Expression of the infectious bronchitis virus spike protein by recombinant vaccinia virus and induction of neutralizing antibodies in vaccinated mice.
Antigenic comparison of feline coronavirus isolates: evidence for markedly different peplomer glycoproteins.
Antigenic variation of porcine transmissible gastroenteritis virus detected by monoclonal antibodies.
Characterization of the structural proteins of the murine coronavirus strain A59 using monoclonal antibodies.
Catabolism of homologous murine monoclonal hybridoma IgG antibodies in mice.
Genetic resistance to mouse hepatitis virus correlates with absence of virus-binding activity on target tissues.
RNA recombination of coronavirus.
Identification of epitopes of immunological importance on the peplomer of porcine transmissible gastroenteritis virus.
Critical epitopes in transmissible gastroenteritis virus neutralization.
Coronavirus JHM induced demyelinating disease: specific domains on the E2-protein are associated with neurovirulence.
Identification of two epitopes in the carboxyterminal 15 amino acids of the E1 glycoprotein of mouse hepatitis virus A59 by using hybrid proteins.
Critical epitopes in transmissible gastroenteritis virus neutralization.
Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence.
The peplomer protein sequence of the M41 strain of coronavirus IBV and its comparison with Beaudette strains.
Coronavirus IBV: virus retaining spike glycopolypeptide S2 but not S1 is unable to induce virus-neutralizing or haemagglutination-inhibiting antibody, or induce chicken tracheal protection.
Antigenic structure of transmissible gastroenteritis virus. II. Domains in the peplomer glycoprotein.
In vivo effects of coronavirus-specific T cell clones: DTH inducer cells prevent a lethal infection but do not inhibit virus replication.
Natural cytotoxicity against mouse hepatitis virus-infected cells. II. A cytotoxic effector cell with a B lymphocyte phenotype.
Antigenic structure of transmissible gastroenteritis virus. I. Properties of monoclonal antibodies directed against virion proteins.
Envelope proteins of avian infectious bronchitis virus: purification and biological properties.
Antigenic variation among murine coronaviruses: evidence for polymorphism on the peplomer glycoprotein, E2.
Epitope-specific antibody response to murine hepatitis virus-4 (strain JHM).
Studies of TGEV spike protein gp195 expressed in E. coli and by a TGE-vaccinia virus recombinant.
Monoclonal antibodies to the S1 spike and membrane proteins of avian infectious bronchitis coronavirus strain Massachusetts M41.
Hybridoma antibodies to the murine coronavirus JHM: characterization of epitopes on the peplomer protein (E2).
Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody.
Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): correlation with biological activities.
Biological and macromolecular properties of murine cells persistently infected with MHV-JHM.
Antigenic relationships of murine coronaviruses: analysis using monoclonal antibodies to JHM (MHV-4) virus.
Survey of respiratory diseases among chicken flocks in Japan for avian infectious bronchitis by the neutralization test with embryo-adapted Beaudette strain.
Utilization of monoclonal antibodies for antigenic characterization of coronaviruses.
In vivo and in vitro models of demyelinating disease: endogenous factors influencing demyelinating disease caused by mouse hepatitis virus in rats and mice.
Antigenic relationships among homologous structural polypeptides of porcine, feline, and canine coronaviruses.
Antigenic variation of avian infectious bronchitis virus during replication in BHK-21 cells.
Immunogenicity and antigenicity of human coronaviruses 229E and OC43.
Genetic variation of neurotropic and non-neurotropic murine coronaviruses.
Antigenic and biological relationships between human coronavirus OC43 and neonatal calf diarrhoea coronavirus.
Antigenic studies on coronavirus. I. Identification of the structural antigens of human coronavirus, strain 229E.
Spectroscopic properties of light-chain derivatives of murine MOPC-315 immunoglobulin A.
Serological relation between calf diarrhea coronavirus and hemagglutinating encephalomyelitis virus.
Antigenic relationship between human coronavirus strain OC 43 and hemagglutinating encephalomyelitis virus strain 67N of swine: antibody responses in human and animal sera.
Haemagglutination by avian infectious bronchitis virus-a coronavirus.
A large-scale systematic survey of SARS-CoV-2 antibodies reveals recurring molecular features.
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance.
Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities.
Stabilization of the SARS-CoV-2 Receptor Binding Domain by Protein Core Redesign and Deep Mutational Scanning.
BSG/CD147 and ACE2 receptors facilitate SARS-CoV-2 infection of human iPS cell-derived kidney podocytes.
SARS-CoV-2 Antibody Response is Associated with Age in Convalescent Outpatients.
Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination.
SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike.
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19.
SARS-CoV-2 infection induces cross-reactive autoantibodies against angiotensin II.
Camel nanobodies broadly neutralize SARS-CoV-2 variants.
mRNA Vaccines Induce Rapid Antibody Responses in Mice.
Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals.
Boosting of Cross-Reactive Antibodies to Endemic Coronaviruses by SARS-CoV-2 Infection but not Vaccination with Stabilized Spike.
The humanized nanobody RBD-1-2G tolerates the spike N501Y mutation to neutralize SARS-CoV-2.
Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals.
SARS-CoV-2 vaccine antibody response and breakthrough infection in dialysis.
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients.
SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy.
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses.
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy.
Quantum Optical Immunoassay: Upconversion Nanoparticle-based Neutralizing Assay for COVID-19.
Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial.
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein after infection and/or vaccination.
The evolution of the mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America.
Molecular switches regulating the potency and immune evasiveness of SARS-CoV-2 spike protein.
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals.
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display.
Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals.
Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles.
Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape.
mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern.
Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines.
Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity.
Serological survey of SARS-CoV-2 incidence conducted at a rural West Virginia hospital.
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant.
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.
Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants.
COVID-19 mRNA Vaccination in Lactation: Assessment of adverse effects and transfer of anti-SARS-CoV2 antibodies from mother to child.
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern.
Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity.
Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines.
Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike.
A Rapid and Affordable Point-of-care Test for Detection of SARS-Cov-2-Specific Antibodies Based on Hemagglutination and Artificial Intelligence-Based Image Interpretation.
Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection.
Vaccine serologic responses among transplant patients associate with COVID-19 infection and T peripheral helper cells.
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates.
Xeno-nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.
Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity.
Next-generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire.
Receptor-binding domain recombinant protein RBD219-N1C1 on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates.
Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers.
Dimeric IgA is a specific biomarker of recent SARS-CoV-2 infection.
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain.
Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease.
Structures of synthetic nanobody-SARS-CoV-2-RBD complexes reveal distinct sites of interaction and recognition of variants.
Mapping Potential Antigenic Drift Sites (PADS) on SARS-CoV-2 Spike in Continuous Epitope-Paratope Space.
Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: preventing COVID-19 and treating tumor progression.
Evidence for Deleterious Antigenic Imprinting in SARS-CoV-2 Immune Response.
Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.
Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies.
Functional characterization of SARS-CoV-2 vaccine elicited antibodies in immunologically na√Øve and pre-immune humans.
Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year.
Combination of a Sindbis-SARS-CoV-2 spike vaccine and Œ±OX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima - Peru.
Divergent early antibody responses define COVID-19 disease trajectories.
Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity.

multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection.
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy.
Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy.
Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis.
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response.
Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies.
Energy Landscape of the SARS-CoV-2 Reveals Extensive Conformational Heterogeneity.
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
SARS-CoV-2 receptor binding domain-specific antibodies activate platelets with features resembling the pathogenic antibodies in heparin-induced thrombocytopenia.
A hemagglutination-based, semi-quantitative test for point-of-care determination of SARS-CoV-2 antibody levels.
LY-CoV1404 potently neutralizes SARS-CoV-2 variants.
SARS -CoV-2 T-cell immunity to variants of concern following vaccination.
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.
Impaired T-cell and antibody immunity after COVID-19 infection in chronically immunosuppressed transplant recipients.
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells.
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity.
A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice.
Insertions in SARS-CoV-2 genome caused by template switch and duplications give rise to new variants of potential concern.
A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope.
Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates.
Human Taste Cells Express ACE2: a Portal for SARS-CoV-2 Infection.
Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells.
Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.
The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD.
An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory.
Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies.
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum.
mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition.
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody.
Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity.
Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2.
Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality.
SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques.
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429.
Analysis of glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein.
Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2.
A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes.
Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model.
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants.
Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period.
Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine.
Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents.
T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity.
Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.
B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies.
A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants.
Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.
Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects.
SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses.
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study.
Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation.
Anti-SARS-CoV-2 Serology persistence over time in COVID-19 Convalescent Plasma Donors.
SARS-CoV-2 seroassay optimization and performance in a population with high background reactivity in Mali.
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD.
Predicting the Efficacy of COVID-19 Convalescent Plasma Donor Units with the Lumit Dx anti-Receptor Binding Domain Assay.
A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies.
Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike.
Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants.
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses.
Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies.
Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motif.
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes.
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening.
Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva.
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity.
Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Na√Øve and Recovered Individuals Following mRNA Vaccination.
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.
Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma Units.
Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants.
Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization.
Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates.
Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters.
Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.
A Novel and Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York.
High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19.
Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants.
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies.
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.
Convalescent plasma for preventing critical illness in COVID-19: A phase 2 trial and immune profile.
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
SARS-CoV-2 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to Campus on Infection Risk Among Community Members.
SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys.
Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization.
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
Rotavirus as an Expression Platform of the SARS-CoV-2 Spike Protein.
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies.
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab 
Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677.
Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses.
Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.
Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses.
SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.
Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant.
Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals.
The basis of a more contagious 501Y.V1 variant of SARS-COV-2.
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.
Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike.
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M‚Ñ¢ vaccination.
Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
SARS-CoV-2 recruits a haem metabolite to evade antibody immunity.
Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain.
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes.
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.
A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.
Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail.
Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets.
Modeling mutational effects on biochemical phenotypes using convolutional neural networks: application to SARS-CoV-2.
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine.
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2.
Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease.
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine.
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
Rigid monoclonal antibodies improve detection of SARS-CoV-2 nucleocapsid protein.
CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-2-infected Cells.
Fever, Diarrhea, and Severe Disease Correlate with High Persistent Antibody Levels against SARS-CoV-2.
Neuropilin-1 Assists SARS-CoV-2 Infection by Stimulating the Separation of Spike Protein Domains S1 and S2.
The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates.
MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease.
Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates.
Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.
Extracellular vimentin as a target against SARS-CoV-2 host cell invasion.
A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.
Kinetics of antibody responses dictate COVID-19 outcome.
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation.
A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.
MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans.
SARS-CoV-2 escape 
Structural basis for broad coronavirus neutralization.
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma.
Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions.
Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.
IgG Antibodies against SARS-CoV-2 Correlate with Days from Symptom Onset, Viral Load and IL-10.
Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials.
Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif.
Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.
Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection.
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.
T cell and antibody functional correlates of severe COVID-19.
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry 
Characterization of SARS-CoV-2 N protein reveals multiple functional consequences of the C-terminal domain.
Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure.
Dysregulated immunity in SARS-CoV-2 infected pregnant women.
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
The Development of a Novel Nanobody Therapeutic for SARS-CoV-2.
High resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19.
Quantitative measurement of IgG to SARS-CoV-2 proteins using ImmunoCAP.
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.
Multiplexed, quantitative serological profiling of COVID-19 from a drop of blood by a point-of-care test.
Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2.
The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition.
Evolution of Antibody Immunity to SARS-CoV-2.
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice.
Durable SARS-CoV-2 B cell immunity after mild or severe disease.
A cell-free antibody engineering platform rapidly generates SARS-CoV-2 neutralizing antibodies.
Global Absence and Targeting of Protective Immune States in Severe COVID-19.
Global Absence and Targeting of Protective Immune States in Severe COVID-19.
COVID-19 neutralizing antibodies predict disease severity and survival.
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.
Ongoing Global and Regional Adaptive Evolution of SARS-CoV-2.
Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies.
Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19.
A multiplex microsphere IgG assay for SARS-CoV-2 using ACE2-mediated inhibition as a surrogate for neutralization.
Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice.
The landscape of antibody binding in SARS-CoV-2 infection.
CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation.
Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors.
Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.
Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2.
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.
COVID-19 and human milk: SARS-CoV-2, antibodies, and neutralizing capacity.
KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney.
AI-guided discovery of the invariant host response to viral pandemics.
A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.
Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model.
Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.
The flexibility of ACE2 in the context of SARS-CoV-2 infection.
Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2.
Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition.
Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles.
SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike.
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility.
Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2.
Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration.
Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies.
Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction.
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility.
Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2.
A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice.
Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies.
Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis.
SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness.
Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community.
Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure.
A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model.
A 3.4-√Ö cryo-EM structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles.
Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells.
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2.
An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation.
Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice.
Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents.
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity.
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.
Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2.
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
Dynamics and significance of the antibody response to SARS-CoV-2 infection.
Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological Sex.
CoVaccine HT‚Ñ¢ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation.
The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State.
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain.
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate.
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV.
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2.
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.
Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19.
Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization.
Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19.
Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis.
Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2.
Critical Sequence Hot-spots for Binding of nCOV-2019 to ACE2 as Evaluated by Molecular Simulations.
Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation.
Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains.
A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies.
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.
SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients.
Review of COVID-19 Antibody Therapies.
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.
Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike.
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding.
Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay.
Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay.
Broad and strong memory CD4 
Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 
CoV3D: A database and resource for high resolution coronavirus protein structures.
Development and validation of IMMUNO-COV‚Ñ¢: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2.
Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies.
Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein.
Structural basis of a public antibody response to SARS-CoV-2.
Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike.
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
A High Through-put Assay for Circulating Antibodies Directed against the S Protein of Severe Acute Respiratory Syndrome Corona virus 2.
The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies.
Rapid generation of neutralizing antibody responses in COVID-19 patients.
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva.
A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding.
Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates.
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models.
Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals.
Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.
IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity.
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model.
Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement.
Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.
Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein.
Structural and functional analysis of a potent sarbecovirus neutralizing antibody.
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.
Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein.
Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.
Analysis of the SARS-CoV-2 spike protein glycan shield: implications for immune recognition.
A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein.
Novel Immunoglobulin Domain Proteins Provide Insights into Evolution and Pathogenesis Mechanisms of SARS-Related Coronaviruses.
Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation.
